BMJ Open

Translating the World Health Organization 25x25 goals into a United Kingdom context: The PROMISE modelling study

Journal:	BMJ Open			
Manuscript ID	bmjopen-2016-012805			
Article Type:	Research			
Date Submitted by the Author:	24-May-2016			
Complete List of Authors:	Cobiac, Linda J.; University of Otago Wellington, Department of Public Health; University of Oxford, The British Heart Foundation Centre on Population Approaches for Non-Communicable Disease Prevention, Nuffield Department of Population Health Scarborough, Peter; University of Oxford, Department of Public Health			
Primary Subject Heading :	Public health			
Secondary Subject Heading:	Health policy, Epidemiology			
Keywords:	PUBLIC HEALTH, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, PREVENTIVE MEDICINE			



Translating the World Health Organization 25x25 goals into a United Kingdom context: The PROMISE modelling study

Linda J Cobiac

Burden of Disease Epidemiology, Equity and Cost Effectiveness (BODE3) Programme, University of Otago, Wellington, New Zealand

British Heart Foundation Centre on Population Approaches for Non-Communicable Disease Prevention, Nuffield Department of Population Health, University of Oxford, Old Road Campus, Headington, Oxford, OX3 7LF, UK

Peter Scarborough

British Heart Foundation Centre on Population Approaches for Non-Communicable Disease Prevention, Nuffield Department of Population Health, University of Oxford, Old Road Campus, Headington, Oxford, OX3 7LF, UK

Corresponding author: Linda Cobiac linda.cobiac@dph.ox.ac.uk

Key words: non-communicable disease, prevention, modelling

Word count (main text): 4098

ABSTRACT

 Objective – Model the impact of targets for obesity, diabetes, raised blood pressure, tobacco use, salt intake, physical inactivity and harmful alcohol use, as outlined in the Global Non-Communicable Disease Action Plan 2013-2020, on mortality and morbidity in the UK population.

Design – Dynamic population modelling study

Setting – UK population

Participants - NA

Main outcome measures – Mortality and morbidity (Years Lived with Disability) from noncommunicable diseases (NCDs) that are averted or delayed. Probability of achieving a 25% reduction in premature mortality from NCDs by 2025 (current WHO target) and a 33% reduction by 2030 (proposed target).

Results – The UK could achieve the 2025 and 2030 targets with only a little additional preventive effort compared to current practice. Achieving all seven risk targets could avert a total of 300,000 deaths (95% uncertainty interval: 250,000 to 350,000) and 1.3 million Years Lived with Disability (1.2 million to 1.4 million) from NCDs by 2025, with the majority of health gains due to reduced mortality and morbidity from heart disease and stroke, and reduced morbidity from diabetes. Potential reductions in morbidity from depression and in morbidity and mortality from dementia at older ages are also substantial.

Conclusions - The global premature mortality targets are a potentially achievable goal for countries such as the UK that can capitalise on many decades of effort in prevention and treatment. High morbidity diseases and diseases in later life are not addressed in the Global NCD Action Plan and targets, but must also be considered a priority for prevention in the UK where the population is ageing and the costs of health and social care are rising.

ARTICLE SUMMARY

Strengths and limitations of the study:

- The study combined functional demographic modelling of population forecasting, logistic regression modelling of 'business-as-usual' trends in NCD rates and NCD risk factors, and dynamic modelling of population health outcomes.
- We simulated the future changes in NCD mortality and morbidity that would occur: (1) with 'business-as-usual'; (2) if the UK could achieve the World Health Organization's risk factor reduction targets; and (3) if all NCD burden could be addressed.
- We also estimated the probability that the UK would meet the current WHO target of a 25% reduction in premature mortality by 2025 and the new target of a 30% reduction by 2030.
- Integrating projections of risk factor and disease trends with a population demographic model that stochastically forecasts trends in mortality, fertility and migration, is an important advance on existing global modelling methods.
- Future work will focus on integrating the health models with other big systems models, such as the AgMIP models [1], which focus on food security under climate change.



BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright

Non-communicable diseases (NCDs) have been recognised as a major challenge for all nations in the 21st century, affecting people of all ages, gender, race and income level[2]. It is a burden that is in large part preventable; closely linked to a range of risky behaviours, including tobacco use, unhealthy diet, physical inactivity and harmful use of alcohol; risks that are themselves closely related to the societies and environments in which we live. In response to the United Nations declaration on addressing prevention and control of NCDs[2], the World Health Organization (WHO) developed a Global NCD Action Plan 2013-2020[3], which outlines global targets for improving prevalence of NCD risk factors (obesity, diabetes, raised blood pressure, tobacco use, salt intake, physical inactivity and harmful use of alcohol) with an overarching goal of achieving a 25% reduction in premature mortality from the four main NCDs (cardiovascular diseases, chronic respiratory diseases, cancers and diabetes) by the year 2025. Global modelling of the risk factor impacts on NCDs shows that premature mortality from the four main NCDs could be reduced globally by 22% in men and 19% in women, between 2010 and 2025, if the targets could be achieved[4].

It is the responsibility of individual countries to initiate actions to achieve the targets, and regularly measure and review national progress[5]. However, it is not clear to what extent the NCD and risk factor targets should guide priorities for action or to what extent progress will reflect a nation's improvement in health. While the four main NCDs are responsible for 87% of all NCD deaths worldwide, they only contribute to 57% of the ill health burden from NCDs[6]. There are also indications that targets for reducing tobacco use could be more ambitious[4]. These concerns are to some extent reflected in the new set of 'Sustainable Development Goals' (SDGs) and targets for 2030 that were adopted by United Nations world leaders in September 2015. The new health-related NCD goals aim to 'promote mental health and well-being' and to strengthen implementation of the WHO Framework Convention on Tobacco Control, alongside a revision of the premature

BMJ Open

mortality goal to a one-third reduction by 2030. In response to the SDGs, the WHO has signalled its intent to expand work on prevention of NCDs in 2016-17[7].

More information is needed about the impact of achieving the WHO risk factor targets on morbidity from NCDs and about the impact on a broad range of NCDs including mental health and neurological disorders. In a study funded by the Richmond Group of Charities[8], PROMISE, we have examined the implications of the WHO risk factor targets for priority setting in the UK. We modelled the impact of meeting the risk factor targets on morbidity and mortality from a wide range of NCDs, and examined whether the UK is likely to achieve a 25% reduction in premature mortality by 2025. In addition, in order to estimate how much of the potentially preventable portion of NCD burden could be addressed by the WHO targets, we evaluated an 'ideal risk reduction' scenario in which everyone in the UK achieves a normal weight, is physically active, non-smoking, without diabetes or raised blood pressure, has an ideal salt intake and does not drink alcohol at harmful levels. In this paper, we report on the results of this study, and consider the implications for setting future targets for risk reduction.

METHODS

We developed a dynamic model for simulating the effect of annual changes in risk factors on annual burden of non-communicable diseases in the UK. The modelling was carried out in two parts. First, we used historical data on risk factors in England to project trends in salt consumption, physical activity, alcohol consumption, smoking, body mass index, diabetes and blood pressure forward to 2025, and then used these trends to estimate the proportional impact on NCDs of achieving the 25x25 targets. Second, we developed a population and mortality forecast model which estimated business-as-usual projections of NCD morbidity and mortality to 2025. This was then used as the baseline to apply the proportional changes in disease, which were calculated in the first model to estimate the impact of achieving the WHO 25x25 targets and the ideal risk reduction on NCD mortality and morbidity.

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright

Risk factor projections model

Historical risk factor data were obtained from the Health Survey for England series[9]. This survey is conducted annually and collects data on a representative sample of community-living adults in England. Annual sample sizes are approximately 11,000 adults aged 18 and over. Data are collected on health behaviour (including diet, smoking, alcohol consumption and physical activity) using a standard questionnaire delivered and recorded by a trained interviewer. Anthropometric data, including body mass index and blood pressure, are recorded by a trained nurse. For the PROMISE project, we compiled a dataset (Stata Version 11) with data on the seven WHO targets from all surveys conducted between 1995 and 2012.

All risk factor projections were stratified by sex and broad age group (18 to 35; 36 to 55; 56+). For each stratum, following a method used for the UK Foresight 'Modelling future trends in obesity and their impact on health' project[10], we modelled the relationship between prevalence of the risk factor (p) and time (t) using the following equation (where *a* and *b* are model parameters):

$$p(\mathbf{t}) = \frac{1}{2} (1 + \tanh(a + b\mathbf{t}))$$

This relationship is convenient for modelling future projections, as it results in smooth changes over time that are constrained between minimum and maximum values of 0 and 100%. For each risk factor, we derived variables from the Health Survey for England dataset to match the risk factor definitions used for the WHO targets[11], and then used logistic regression to fit the above equation, with survey year providing the time variable. We then projected prevalence forward to 2025, assuming the equations hold until this time. Table 1 provides further details regarding projections for each of the seven risk factors.

Relative risks for the relationship between risk factors and diseases were taken from meta-analyses of prospective studies (Table 2). In most cases, these were restricted to meta-analyses of cohort studies, but in some cases meta-analyses that combined results from cohort studies and prospective

BMJ Open

case control studies (i.e. nested in cohort studies) were also included. With the exception of salt, the relationship between the risk factors and disease outcomes was modelled directly, and preference was given to relative risks that were adjusted for the most of the other risk factors. The effect of salt on blood pressure levels was modelled using a meta-analysis of salt reduction trials[12], and then the subsequent impact of blood pressure on disease was modelled as described above.

The evidence relating a link between the risk factors and both dementia and depression is less established than for the other disease outcomes. In some cases the mechanisms are unclear[13], or previous results investigating the relationship have been highly heterogeneous[14]. Meta-analyses of the relationship between risk factors and depression and dementia are often not based on analyses adjusted for other risk factors, increasing the risk of confounding[15]. For this reason, we present two sets of modelled results, for analyses that both include and do not include depression and dementia as outcomes.

Evaluating population impact fractions (PIFs)

The WHO targets and the ideal risk reduction scenarios for salt consumption, physical activity, alcohol consumption, smoking, body mass index, diabetes and blood pressure are described in Table 2. Our implementation of the WHO targets depended on whether the risk reductions were relative reductions (e.g. a 30% reduction in smoking) or absolute reductions (e.g. halt the rise in obesity). For relative reductions in the prevalence of a risk factor (smoking, blood pressure, alcohol, physical inactivity), the reduction was applied to the projected prevalence in every year between 2010 and 2025. For absolute reductions in the prevalence of a risk factor (obesity, diabetes), the target prevalence was assumed to be the actual prevalence in 2010. For relative reductions in a mean consumption of a risk factor (salt), the reduction was applied in every year between 2010 and 2025, and the standard deviation of the distribution for each age-sex stratum was assumed to remain constant (i.e. the entire distribution was shifted). The ideal risk reduction scenarios were based on definitions in the Global Burden of Disease study[16].

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright.

1
2
3
2 3 4 5 6 7 8 9 10
5
ю 7
/ 8
a
10
12
13
14
15
16
17
18
19
20
21
22
23
24
26
27
28
29
30
$\begin{array}{c} 1\\ 1\\ 2\\ 1\\ 3\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\$
32
33
34
35
36
37
38 39
39 40
40 41
42
43
44
45
46
47
48
49
50
51
52 53
53 54
54 55
55 56
50 57
58
59
60
-

Table 1 Methods for the projection of risk factors.

Risk factor	WHO definition	HSE years used	Comments
Overweight and obesity	Overweight: adults with BMI between 25 and 30. Obese: adults with BMI greater than 30.	All years between 1995 and 2012.	Five BMI categories were projected: ≤20; 20-≤25; 25-≤30; 30 ≤35; >35. The relationship between prevalence of each BM category and survey year was modelled separately Projections combined proportionately, in order to ensure th sum of all BMI categories was exactly 100% in any year.
Smoking	Prevalence of adult population currently using any tobacco product.	All years between 1995 and 2012.	The prevalence of current smoking and never smoking wer projected. The prevalence of former smoking was assume to be 100% - prevalence of never and current smokers.
Diabetes	Prevalence of raised blood glucose, or medication for raised glucose.	1998; 2003; 2006; 2009; 2010; 2011; 2012	We used prevalence of doctor-diagnosed diabetes. The WH definition could not be used due to lack of representativ data in England.
Blood pressure	PrevalenceofadultpopulationwithSBP≥140mmHgorDBP≥90mmHg.	All years between 1995 and 2012.	Prevalence of raised blood pressure projected. To estimat health impact of raised blood pressure, relative risks ar based on median SBP of age-sex-raised blood pressur groups in HSE2012.
Alcohol	Prevalence of heavy episodic drinking (consuming ≥60g alcohol on a single occasion at least monthly)	All years between 1998 and 2012.	Three alcohol categories were projected: abstainers (≤1 alcohol per week); non-harmful drinkers; harmful drinkers Projections were combined proportionately, in order t ensure the sum of all alcohol categories was exactly 100% i any year. Relationships between alcohol and diseas outcomes were based on difference in weekly alcoho consumption between alcohol groups, estimated using th HSE2012. A dummy variable was included in regressio analyses to isolate the impact of changes in alcoho measurement in the HSE in 2006.
Physical inactivity	Prevalence of physical inactivity (less than 150 minutes of moderate- intensity activity per week, or equivalent).	1997; 1998; 2003; 2004; 2006; 2008; 2012	Three physical activity categories were projected: sedentar (≤0.2METh/d); not sedentary, but inactive; active. Logisti regression models estimated the trend in the prevalence of first two groups combined, and we separated between thes two groups based on proportion of adults in HSE2012. Th prevalence of activity was assumed to be 100% - prevalence of inactivity. Data between 1997 and 2012 were available o a consistent measure of inactivity, but only HSE201 measured inactivity equivalent to the WHO definition Regression models were based on the consistent measure of inactivity then adjusted according to the difference in th two measures recorded in HSE2012. The risk relationshi between physical activity and disease outcomes based o difference in amount of physical activity (METh/d) betwee physical activity categories, estimated using HSE2012 data.
Salt (mediated by blood pressure)	Mean population intake of salt.	2008; 2009; 2010; 2011*	National Diet and Nutrition Survey urinary analyses data use to assess trends by age-sex groups. No trends apparent, s projections assume no change from current mea consumption levels. Mean and standard deviations used t generate normal distributions of salt consumption, whic were converted into salt-related blood pressure using th prevalence of normotensives and hypertensives derived from the blood pressure projections, and parameters drawn from meta-analyses of salt reduction trials.

Risk factor	Risk definitions and targets	Modelled NCD outcomes
Overweight and obesity	Overweight: adults with BMI between 25 and 30. Obese: adults with BMI greater than 30. WHO target: Halt the rise in obesity. Ideal target: Everyone normal weight (BMI 20-25; median 22)	CHD[37]; Stroke[37]; Diabetes[37]; Cirrhosis[37]; Colorectal cancer[37]; Kidney cancer[37]; Breast cancer[37]; Pancreas cancer[38]; Liver cancer[37]; Hypertensive heart disease[37]; Kidney disease[37]; Depression[39]; Dementia[40]
Smoking	Prevalence of adult population currently using any tobacco product. WHO target: 30% relative reduction. Ideal target: No current or past use of tobacco	COPD[41]; CHD[41]; Stroke[41]; Diabetes[42]; Lung cancer[43]; Oesophagus cancer[43]; Larynx cancer[43]; Stomach cancer[43]; Liver cancer[44]; Pancreas cancer[43]; Kidney cancer[43]; Cervix cancer[43]; Bladder cancer[43]; Depression[45]; Dementia[46]
Diabetes	Prevalence of doctor-diagnosed diabetes. WHO target: Halt the rise in diabetes. Ideal target: No prevalence of diabetes	CHD[47]; Stroke[48]; Depression[49] Dementia[50]
Blood pressure	Prevalence of adult population with SBP≥140mmHg or DBP≥90mmHg. WHO target: 25% relative reduction in raised blood pressure. Ideal target: No prevalence of raised blood pressure	CHD[51]; Stroke[51]
Alcohol	Prevalence of heavy episodic drinking (consuming ≥60g alcohol on a single occasion at least monthly) and per capita consumption. WHO target: 10% relative reduction. Ideal target: No consumption of alcohol	CHD[52]; Stroke[53]; Hypertensive heart disease[52]; Diabetes[54]; Cirrhosis[55]; Liver cancer[56]; Mouth cancer[56]; Colorectal cancer[56]; Breast cancer[56]; Oesophagus cancer[56]
Physical inactivity	Prevalence of physical inactivity (less than 150 minutes of moderate-intensity activity per week, or equivalent). WHO target: 10% relative reduction. Ideal target: Everyone physically active	CHD*; Stroke*; Diabetes*; Breast cancer[30]; Colorectal cancer[30], Depression[57]; Dementia[58]
Salt (mediated by blood pressure)	Mean population intake of salt. WHO target: 30% relative reduction. Ideal target: Mean intake of 1000mg/day	CHD[12, 51]; Stroke[12, 51]

Table 2 WHO risk factor definitions, target levels and modelled disease outcomes.

NB. CHD: Coronary Heart Disease; COPD: Chronic Obstructive Pulmonary Disease. * Wahid et al. In press, Journal of American Heart Association.

Using the disease projections and the relative risk estimates, we calculated PIFs for each disease-risk factor relationship, in each age-sex stratum, in every year between 2010 and 2025. PIFs estimate the proportion of disease in a population that is removed under a counterfactual scenario (in this case, in the scenario where the WHO targets or ideal levels are achieved). We calculated PIFs using the following equation, where there are k risk factor categories, p_i is the proportion of the population in risk factor category i in the estimate year based on projections, p'_i is the proportion of the

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright

population in risk factor category *i* in the estimate year based on achieving the WHO or ideal risk reduction target, and *RR_i* is the relative risk for the disease in risk factor category *i*:

$$PIF = \frac{\sum_{i=1}^{k} p_i RR_i - \sum_{i=1}^{k} p'_i RR_i}{\sum_{i=1}^{k} p_i RR_i}$$

We present results separately for each risk factor (i.e. when only the single risk factor target is achieved) and in combination (i.e. if all risk factor targets are achieved). For the combined scenario, we multiplicatively combined PIFs for blood pressure, diabetes, physical activity, BMI, alcohol and tobacco, adjusting for double-counting where there are interdependencies in risks (e.g. physical activity affects CHD directly and via changes in BMI; BMI affects CHD directly and via changes in blood pressure). These methods for avoiding double counting are described in further detail in Appendix 1. Where risk factors were both mediating variables and the subject of WHO targets (blood pressure and diabetes), we took the larger of the effects. For example, we calculated the combined effects of meeting physical activity, BMI and salt targets on BP (assuming they are independent i.e. additive), we then calculated the effect of the hypertension target on BP, and took only the larger of these two effects. Similarly, we calculated the combined effect of meeting physical activity and BMI targets on diabetes, estimated the effect of the diabetes target on diabetes prevalence, and took only the larger of the two effects.

We calculated 95% uncertainty intervals for all PIFs, based on lognormal distributions for the relative risks and normal distributions for other variables as reported in the literature (e.g. effect of salt on blood pressure), using Monte Carlo analysis[17].

Disease projections model

The PIFs were applied to projected disease rates in a UK population and mortality forecast model in order to estimate disease outcomes of meeting WHO targets. The model was built in R (version 3.1.2) using packages *demography* and *systemfit*.

BMJ Open

The UK population was forecast out to 2025 based on historical demographic patterns. We used data from the period 1938 to 2010, obtaining population and mortality from the Human Mortality Database[18], fertility from the Human Fertility Database[19], and deriving net migration for the same time period, from these data. These demographic rates were smoothed using penalised regression splines. We then fitted functional demographic models[20] to mortality, fertility and migration rates from 1938 to 2010, and used these models to forecast future rates out to 2030. Finally, we simulated the population over time to 2030, using bootstrapping to estimate uncertainty in the population from the errors in the mortality, fertility and migration models.

For projecting disease-specific mortality, we developed regression models using methods described by Salomon and Murray[21] that ensure that disease-specific mortality projections are consistent with the projected all-cause mortality envelope. We obtained cause-specific mortality data from the WHO database[22], focusing on deaths coded using the most recent version of the International Classification of Diseases (ICD-10). ICD-10 was only adopted in the UK in 2001, which limited the analyses to only 10 years of past data points. Including deaths coded using the preceding ICD-9 version, increased the years of available data back to 1980, but although we applied translations from ICD-9 to ICD-10[23], there remained visible anomalies in the data before/after the change in coding for some disease. Concerned that this could lead to incorrect predictions of trends, we therefore restricted the analyses to the ICD-10 coded data, but broadened our data set to include data from all EU countries, which have similar high income and low mortality profile, and included GDP per capita into the model as an explanatory variable.

Deaths coded to heart failure (I50) were redistributed to the primary causes (e.g. coronary heart disease (CHD), hypertensive heart disease, COPD and chronic kidney disease)[24]. Deaths were grouped into three age groups: <35, 35-64 and 65+. For each age group, we determined country-specific mortality for each risk factor-related disease, and all other diseases, as a proportion of all-cause mortality in each country. Using methods described by Salomon and Murray[21] we specified

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright

a multivariate normal model for the log of the ratios of each cause fraction to the cause fraction for all other diseases, using the log of all-cause mortality rate and GDP per capita[25] as explanatory variables. We then derived parameter values for the disease projections models, for each age group, using seemingly unrelated regression[26].

To project disease rates forward in time for the UK, we applied the mortality projections from our population forecasts and GDP projections from the World Bank[25] in the disease projections models, to determine the annual average change in disease rates for the UK out to 2030.

Evaluating disease burden

To determine the future changes in population if the WHO or ideal risk reduction targets are achieved we first calculated the new population mortality, using the PIFs to determine future changes in mortality from the NCDs. We then re-simulated the future population out to 2030, using the new rates of mortality, but assuming no change in forecasts of fertility and migration.

Effects on premature mortality were estimated as the change in probability of death from NCDs between the ages of 30 and 69[3]. As was done in the global modelling of the WHO NCD reduction targets[4], our estimate was unconditional, in that it excluded deaths from other causes (e.g. injuries), but due to the broader range of diseases of interest in the PROMISE study, we included all NCDs, rather than restricting the analysis to the four main NCD groups (cardiovascular, cancer, diabetes and chronic respiratory diseases).

We defined the morbidity burden associated with non-communicable diseases as the reduction in one year of life at full health. This was calculated at each age and sex, from Global Burden of Disease estimates of prevalent years lived with disability (YLDs). We included a business-as-usual trend in morbidity if there had been a significant change in Global Burden of Disease YLD estimates between 1990 and 2010. For diabetes and depression, we estimated a morbidity effect of achieving the WHO targets, which we estimated using the PIFs for these diseases in the same way that the PIFs were applied to mortality for all other NCDs.

RESULTS

With a continuation of current trends in mortality, fertility and migration, the number of 30 to 69 year olds in the UK population is expected to increase from around 32.5 million in 2010 to 33.4 million in 2025, with the proportion of the whole population aged over 70 rising from 12.5% in 2010 to 16.2% by 2025. With business-as-usual, the probability of premature mortality (30-69 years) from non-communicable diseases among men is expected to fall from 17.6% in 2010 to 13.7% in 2025 (Figure 1). This equates to a relative reduction of 22%, which is just short of the WHO 25% reduction target. Premature mortality among women, is expected to reach the WHO target, falling from 11.9% in 2010 to 8.9% in 2025 (Figure 1), which equates to a relative reduction of 25%. If we assume trends in risk factors and diseases continue to 2030, the outcomes follow the same pattern, with men (30%) falling short of the 33% reduction target and women (33%) just reaching it.

There is added benefit from achieving the WHO 2025 behavioural risk factor targets (Table 3), which ranges from an added relative reduction of 0.1% (reduced physical inactivity) to 2.3% (rise in obesity halted). The combined effect of achieving all seven risk factor targets (relative reduction of 6.1% for men and 3.0% for women) is sufficient for both men and women to reach the 25% premature mortality reduction target by 2025 (Figure 1). Achieving the WHO targets would, however, achieve only a quarter of what could potentially be achieved for men and less than a fifth of what could potentially be achieved for men and less than a fifth of what could potentially be achieved for women.

Achieving all seven behavioural risk factor targets would avert a total of 300,000 deaths (at all ages) and 1.3 million YLDs from the reductions in related NCDs (excluding effects on depression and dementia) between 2010 and 2025 (Table 4). The majority of improvements in mortality are due to fewer deaths from CHD and stroke, while the majority of improvements in morbidity are due to reduced rates of diabetes, CHD and stroke (Figure 2). Figure 2 also shows that there is potentially a substantial additional gain in morbidity from reduced rates of depression in the 30-69 and 70+ age

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright

groups; and substantial additional gains in both morbidity and mortality from reduced rates of dementia in 70+ year olds.

The results demonstrate that, for the UK, achieving the obesity target will result in the biggest overall impact on mortality and morbidity (Figure 3). Halting the rise in diabetes and achieving a 30% reduction in salt intake would also achieve a large impact on NCD mortality, and reducing tobacco consumption by 30% would have a large impact on morbidity.

Over time, achieving the combination of WHO risk factor targets would address an increasing proportion of the health that could potentially be gained if everyone could adjust their risk behaviour to ideal levels in 2010 (Figure 4 and Appendix 2 for deaths and YLDs averted under the ideal risk scenario). Taking both morbidity and mortality into account, by 2025, 29% of the health gain would be achieved for men and 26% for women. If we assume trends in risk factors and diseases continue beyond 2025, the proportions would reach 35% for men and 33% for women by 2030.

BMJ Open

	WHO risk factor targets		Ideal risk reduction		Proportion of ideal risk addressed by meeting WHO target	
	Men	Women	Men	Women	Men	Women
Business-as-usual	22%	25%				
Additional reduction if a	chieving risk factor target	ts or ideal risk scenario:				
Obesity	2.3% (1.6% to 2.9%)	1.1% (0.3% to 1.9%)	7.9% (5.9% to 9.8%)	4.8% (2.6% to 7.1%)	29%	24%
Tobacco use	0.6% (0.6% to 0.7%)	0.6% (0.6% to 0.7%)	12.1% (10.1% to 14.0%)	9.7% (8.2% to 11.1%)	5%	7%
Diabetes	1.4% (1.2% to 1.7%)	0.7% (0.6% to 0.8%)	2.7% (2.2% to 3.2%)	1.4% (1.2% to 1.7%)	53%	51%
Raised blood pressure	0.4% (0.4% to 0.4%)	0.2% (0.2% to 0.2%)	1.6% (1.6% to 1.7%)	0.7% (0.7% to 0.8%)	25%	25%
Salt intake	0.8% (0.8% to 0.9%)	0.3% (0.3% to 0.3%)	2.1% (2.0% to 2.2%)	0.7% (0.7% to 0.8%)	39%	40%
Harmful alcohol use*	0.6% (0.4% to 0.8%)	0.3% (0.22% to 0.5%)	0.9% (-4.6% to 4.0%)	3.2% (-1.08% to 6.9%)	62%	11%
Physical inactivity	0.1% (0.08% to 0.1%)	0.1% (0.0% to 0.1%)	1.1% (0.81% to 1.4%)	0.6% (0.4% to 0.7%)	10%	10%
Combined scenario	6.5% (5.4% to 7.5%)	3.2% (2.2% to 4.1%)	26.2% (21.9% to 29.7%)	18.4% (14.3% to 22.2%)	25%	17%

NB. Values are mean and 95% uncertainty intervals. * Low-level consumption of alcohol is associated with a decreased risk of some diseases (e.g. CHD, hypertensive heart disease and diabetes), which partly counter the modelled health benefits of abstaining from alcohol.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright.

	30-	69 years	70+ years		
	Men	Women	Men	Women	
Deaths					
Obesity	13,000 (8,900 to 17,000)	4,500 (500 to 8,600)	47,000 (34,000 to 60,000)	26,000 (11,000 to 40,000)	
Tobacco use	5,100 (4,800 to 5,400)	4,300 (4,100 to 4,400)	14,000 (13,000 to 15,000)	15,000 (14,000 to 15,000)	
Diabetes	7,200 (5,900 to 8,600)	2,500 (2,000 to 2,900)	38,000 (30,000 to 45,000)	32,000 (26,000 to 38,000)	
Raised blood pressure	5,700 (5,400 to 6,100)	2,300 (2,100 to 2,500)	25,000 (24,000 to 26,000)	23,000 (22,000 to 24,000)	
Salt intake	9,000 (8,700 to 9,400)	2,500 (2,400 to 2,600)	38,000 (37,000 to 39,000)	26,000 (25,000 to 27,000)	
Harmful alcohol use	4,900 (3,000 to 6,900)	2,000 (1,200 to 2,800)	11,000 (7,100 to 16,000)	6,100 (800 to 11,000)	
Physical inactivity	920 (660 to 1,200)	320 (240 to 400)	4,300 (3,200 to 5,400)	3,900 (2,800 to 4,900)	
Combined scenario	38,000 (32,000 to 44,000)	13,000 (8,500 to 17,000)	150,000 (130,000 to 170,000)	99,000 (79,000 to 120,000)	
YLDs					
Obesity	79,000 (66,000 to 93,000)	50,000 (38,000 to 63,000)	150,000 (120,000 to 170,000)	98,000 (66,000 to 130,000)	
Tobacco use	20,000 (20,000 to 21,000)	25,000 (25,000 to 26,000)	27,000 (26,000 to 28,000)	37,000 (36,000 to 38,000)	
Diabetes	190,000 (190,000 to 190,000)	160,000 (160,000 to 160,000)	330,000 (320,000 to 340,000)	290,000 (290,000 to 300,000)	
Raised blood pressure	18,000 (17,000 to 19,000)	12,000 (11,000 to 13,000)	40,000 (38,000 to 42,000)	31,000 (29,000 to 33,000)	
Salt intake	29,000 (28,000 to 30,000)	14,000 (14,000 to 15,000)	60,000 (57,000 to 62,000)	34,000 (33,000 to 36,000)	
Harmful alcohol use	6,200 (-18,000 to 30,000)	-280 (-8,700 to 8,100)	14,000 (-25,000 to 53,000)	3,100 (-12,000 to 18,000)	
Physical inactivity	6,200 (5,300 to 7,000)	5,500 (4,700 to 6,200)	13,000 (11,000 to 15,000)	13,000 (11,000 to 14,000)	
Combined scenario	260,000 (240,000 to 280,000)	200,000 (190,000 to 210,000)	480,000 (430,000 to 520,000)	370,000 (350,000 to 400,000)	

NB. Values are mean and 95% uncertainty intervals..

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright.

BMJ Open

DISCUSSION

There have been considerable achievements in addressing the risks for non-communicable disease in the UK over the last three decades. Although prevalence of obesity and diabetes have risen, initiatives such as increasing access to blood pressure-lowering drugs, reducing salt in processed foods, and strengthening tobacco control, have all contributed to the reduction in these risk factors over time. These changes in lifestyle behaviours, along with advances in treatment, have contributed to the reduction in non-communicable diseases that we observed. Our projections show that if these trends continue, there is likely to be a substantial further reduction in NCD burden by 2025, which will see the UK very nearly reach the current WHO target of 25% reduction in premature mortality and very likely reach the proposed 30% reduction by 2030.

It will be critical that past investments in prevention (and treatment) are sustained so that the UK does not lose the momentum built over previous decades. Preventive efforts must also be increased if the UK is to meet the 2025 target. While the targets do provide a worthwhile objective, a further two-thirds of the preventable NCD burden could potentially be reduced with an even more ambitious prevention program in the future.

Although current WHO targets focus on premature mortality, our modelling predicted substantial added benefits from reduced NCD morbidity, particularly at older ages. Around 16% of Government spending in the UK is allocated to health, which is high compared to other European countries[27]. The large reductions in NCD burden, particularly for CHD, stroke, diabetes, depression and dementia, would help reduce these costs. The social and economic burden of diseases such as depression and dementia is also high. Depression for example is associated with increased workplace absenteeism and reduced productivity[28], and dementia is associated with substantial social care costs[29]. In 2012 the cost of health and social care services for dementia patients in the UK was greater than the costs of CHD, stroke and cancer care combined[29].

Unfortunately the drivers of mental and neurological disorders, despite a high global burden, are poorly understood[30]. Further research is needed to strengthen the epidemiological evidence of the

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright

links between lifestyle risks and prevention of diseases, such as depression and dementia, and to better understand how prevalence of these diseases may in turn increase risk of other NCDs. In the UK, funding for dementia and mental health research is low in comparison to the size of the burden[29, 31]. However, a review of costs and burden of mental and neurological disorders in the EU estimated that the return on investment in research would be highly favourable when taking the full cost to society into account[32].

Cost-effectiveness analysis can be used to identify which interventions will provide best value-formoney. Modelling of interventions for improving diet and body mass in England, suggest that fiscal measures and regulation may be more cost-effective than more individually targeted approaches such as physician counselling and worksite programs[33], which is consistent with findings from modelling studies in comparable high income countries such as Australia[34, 35] and New Zealand[36]. But further work is needed to identify the most effective and cost-effective interventions for addressing a wider range of risk factor targets in the UK, including a number of dietary risks associated with a high NCD burden that are not included in the WHO targets (e.g. fruits and vegetables, fats and cholesterol[30]). Modelling is also needed to better understand and quantify the health impacts of underlying drivers of change, such as global marketing and trade, the design of urban environments and climate change.

This modelling study contributes to the evidence about the potential impact of changes in risk factor prevalence, but to implement change evidence is needed on interventions designed to tackle behavioural risk factors. The relative magnitude of health gain associated with the WHO risk factor targets is not necessarily a good guide for setting priorities for intervention. The apparently smaller benefits of addressing physical inactivity and harmful alcohol use, for example, are in large part because the WHO targets are relatively modest. The modelling of alcohol targets also does not capture any benefits from reduced injury rates, which fall outside of the NCD focus of the WHO targets. In addition, the modelling of some risk factors was limited by the available data (e.g. selfreported physical activity) and WHO definitions (e.g. prevalence of hypertension rather than the full distribution of blood pressure).

BMJ Open

Early population health impact studies typically modelled effects on a population cohort without forward projection of disease trends or they modelled effects on a population cohort forward in time without replacement (i.e. following the current adult population until death or end of projection). In evaluating global NCD impact of the WHO targets, Kontis et al[4] advanced this approach by modelling the population impacts between 2010 and 2025 in three five-year intervals, incorporating projections of disease trends and allowing for population growth and ageing between each modelled time interval. We have taken the modelling a step further by incorporating risk factor prevalence rates and model outputs of disease rates that are directly comparable to past trends, and integrating this with a population demographic model that stochastically forecasts trends in mortality, fertility and migration. This approach could facilitate future integration with other models, including economic models (e.g. AgMIP models, which focus on food security under climate change[1]) allowing health outcomes to be included in broader systems modelling studies. In addition, while focused on a select range of WHO risk factor targets and NCD outcomes for these analyses, the model could potentially be adapted to address a more diverse range of risks factors and disease outcomes in the future.

This modelling study illustrates the large health gains that could be achieved by addressing unhealthy risk factors for disease. For countries such as the UK that can capitalise on many decades of effort in prevention and treatment, the WHO premature mortality target is an achievable goal. But with a further two-thirds of the NCD burden still potentially preventable, it is imperative that the UK capitalises on the momentum of past decades with further effort in prevention. For low- and middle-income countries the potential benefits are likely to be even greater[4], as is the need for evidence to develop cost-effective policies for prevention in these countries. Given the growing global burden of diseases such as diabetes, depression and dementia, the WHO should consider future global targets that provide incentives for addressing these diseases, which carry a high health burden for the individual and place a substantial burden on health and social care systems in society.

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright

ACKNOWLEDGMENTS

We thank Jamie Sims and Jaithri Ananthapavan for assistance with coding physical activity MET values in the Health Survey for England.

COMPETING INTERESTS

All Unified authors have completed the Competing Interest form at www.icmje.org/coi disclosure.pdf (available on request from the corresponding author) and declare (1) LC and PS have support from the Richmond Group of Charities that (www.richmondgroupofcharities.org.uk) for the submitted work; (2) LC and PS have no relationships with any companies that might have an interest in the submitted work in the previous 3 years; (3) their spouses, partners, or children have no financial relationships that may be relevant to the submitted work; and (4) LC and PS have no non-financial interests that may be relevant to the submitted work."

AUTHOR CONTRIBUTIONS

LC and PS conceived of the study, collected and analysed the data, interpreted the results and contributed to writing and editing the manuscript.

ETHICS APPROVAL

Not required

FUNDING

The study was funded by a competitive grant from the Richmond Group of Charities (www.richmondgroupofcharities.org.uk). The funders played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. The researchers were independent of the funder. All authors had

Transparency declaration: The lead author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

DATA SHARING

able No additional data available.

REFERENCES

1. Rosenzweig C, Jones J, Hatfield J, et al. The agricultural model intercomparison and improvement project (AgMIP): protocols and pilot studies. Agricultural and Forest Meteorology. 2013;170:166-82.

2. United Nations. Political declaration of the High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases. United Nations General Assembly, Sixty-sixth session, Agenda item 117, 2011.

3. WHO. Global action plan for the prevention and control of noncommunicable diseases 2013–2020. Geneva: World Health Organization, 2013.

4. Kontis V, Mathers CD, Rehm J, et al. Contribution of six risk factors to achieving the 25× 25 non-communicable disease mortality reduction target: a modelling study. The Lancet. 2014;384(9941):427-37.

5. Beaglehole R, Bonita R, Ezzati M, et al. NCD Countdown 2025: accountability for the 25× 25 NCD mortality reduction target. The Lancet. 2014;384(9938):105-7.

6. Pearce N, Ebrahim S, McKee M, et al. The road to 25× 25: how can the five-target strategy reach its goal? The lancet global health. 2014;2(3):e126-e8.

7. WHO. Health in 2015: from MDGs, Millennium Development Goals to SDGs, Sustainable Development Goals. Geneva: World Health Organization, 2015.

8. The Richmond Group of Charities. [Available from: http://www.richmondgroupofcharities.org.uk/.

9. Joint Health Surveys Unit. Health Survey for England 2013 (and previous editions). Leeds: Health and Social Care Information Centre, 2014.

10. McPherson K, Marsh T, Brown M. Foresight. Tackling obesities – modelling future trends in obesity and the impact on health. London: Government Office for Science, 2007.

11. WHO. Noncommunicable diseases global monitoring framework: indicator definitions and specifications. Geneva: World Health Organization, 2014.

BMJ Open

2
3
3
4
5
6
0
7
8
0
9
10
11
10
12
13
14
15
15
16
17
10
10
19
20
2 3 4 5 6 7 8 9 10 1 12 3 4 15 6 7 8 9 10 1 12 3 4 5 6 7 8 9 10 1 12 3 4 5 6 7 8 9 10 1 12 3 4 5 6 7 8 9 10 1 2 2 3 4 5 6 7 8 9 10 1 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
21
22
23
20
24
25
26
20
27
28
20
29
30
31
22
32
33
34
25
30
36
37
20
30
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

12. He FJ, Li J, MacGregor GA. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. BMJ. 2013;346.

13. Baumgart M, Snyder HM, Carrillo MC, et al. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. Alzheimer's & Dementia. 2015;11(6):718-26.

14. Valkanova V, Ebmeier KP. Vascular risk factors and depression in later life: a systematic review and meta-analysis. Biol Psychiatry. 2013;73(5):406-13.

15. Cheng G, Huang C, Deng H, et al. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J. 2012;42(5):484-91.

16. Lim S, Vos T, Flaxman A, et al. The burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions 1990-2010: a systematic analysis. The Lancet. 2013;380(9859):2224-60.

17. Fishman G. Monte Carlo: concepts, algorithms, and applications. New York: Springer-Verlag 1995.

18. University of California Berkeley (USA), Max Planck Institute for Demographic Research (Germany). Human Mortality Database [Available from: www.mortality.org.

19. Max Planck Institute for Demographic Research (Germany), Vienna Institute of Demography (Austria). Human Fertility Database [Available from: www.humanfertility.org.

20. Hyndman RJ, Booth H, Yasmeen F. Coherent mortality forecasting: the product-ratio method with functional time series models. Demography. 2013;50(1):261-83.

21. Salomon JA, Murray CJ. The epidemiologic transition revisited: compositional models for causes of death by age and sex. Population and Development Review. 2002;28(2):205-28.

22. World Health Organization. WHO Mortality Database [Available from: http://www.who.int/healthinfo/statistics/mortality_rawdata/en/.

23. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright

BMJ Open

60

24. Naghavi M, Makela S, Foreman K, et al. Research Algorithms for enhancing public health utility of national causes-of-death data. Popul Health Metr. 2010;8:9.

25. [Available The World Bank. World Development Indicators from: http://data.worldbank.org/data-catalog/world-development-indicators.

26. Greene WH. Econometric analysis. 5th ed. Upper Saddle River, New Jersey: Prentice Hall; 2003.

27. WHO. National health accounts: country health information Geneva: World Health Organization; 2015 [Available from: http://apps.who.int/nha/database/Country_Profile/Index/en.

28. Donohue JM, Pincus HA. Reducing the societal burden of depression. Pharmacoeconomics. 2007;25(1):7-24.

29. Luengo-Fernandez R, Leal J, Gray A. UK research spend in 2008 and 2012: comparing stroke, cancer, coronary heart disease and dementia. BMJ open. 2015;5(4):e006648.

30. Forouzanfar MH, Alexander L, Anderson HR, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 2015;386:2287-323.

31. Kingdon D. Health research funding: Mental health research continues to be underfunded. BMJ. 2006;332(7556):1510.

32. Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(10):718-79.

33. Cecchini M, Sassi F, Lauer JA, et al. Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness. The Lancet. 2010;376(9754):1775-84.

34. Cobiac LJ, Vos T, Doran C, et al. Cost-effectiveness of interventions to prevent alcohol-related disease and injury in Australia. Addiction. 2009;104(10):1646-55.

35. Cobiac LJ, Vos T, Veerman JL. Cost-effectiveness of interventions to reduce dietary salt intake. Heart. 2010;96(23):1920-5.

BMJ Open

36. Nghiem N, Blakely T, Cobiac ⊔, et al. Health and economic impacts of eight different dietary salt reduction interventions. PLoS ONE. 2015;10(4).

37. Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. The Lancet. 2009;373(9669):1083-96.

38. Norat T, Aune D, Vieira R, et al. The Associations between Food, Nutrition and Physical Activity and the Risk of Pancreatic Cancer. WCRF/AICR Systematic Literature Review Continuous Update Project Report, 2011.

39. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220-9.

40. Beydoun M, Beydoun H, Wang Y. Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis. Obes Rev. 2008;9(3):204-18.

Thun MJ, Apicella LF, Henley SJ. Smoking vs other risk factors as the cause of smoking-41. attributable deaths. Confounding in the courtroom. JAMA. 2000;284(6):706-12.

42. Willi C, Bodenmann P, Ghali WA, et al. Active smoking and the risk of type 2 diabetes: A systematic review and meta-analysis. JAMA. 2007;298(22):2654-64.

43. Gandini S, Botteri E, lodice S, et al. Tobacco smoking and cancer: A meta-analysis. Int J Cancer. 2008;122(1):155-64.

44. Lee Y-CA, Cohet C, Yang Y-C, et al. Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. Int J Epidemiol. 2009:dyp280.

45. Luger TM, Suls J, Vander Weg MW. How robust is the association between smoking and depression in adults? A meta-analysis using linear mixed-effects models. Addict Behav. 2014;39(10):1418-29.

46. Zhong G, Wang Y, Zhang Y, et al. Smoking Is Associated with an Increased Risk of Dementia: A Meta-Analysis of Prospective Cohort Studies with Investigation of Potential Effect Modifiers. PLoS ONE. 2015;10(3):e0118333.

47. Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia. 2014;57(8):1542-51.

48. Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775 385 individuals and 12 539 strokes. The Lancet. 2014;383(9933):1973-80.

49. Rotella F, Mannucci E. Diabetes mellitus as a risk factor for depression. A meta-analysis of longitudinal studies. Diabetes Res Clin Pract. 2013;99(2):98-104.

50. Gudala K, Bansal D, Schifano F, et al. Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies. Journal of diabetes investigation. 2013;4(6):640-50.

51. Lewington S. Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (vol 360, pg 1903, 2002). Lancet. 2003;361(9362):1060-.

52. Shield KD, Parry C, Rehm J. Chronic diseases and conditions related to alcohol use. Alcohol research: current reviews. 2014;35(2):155.

53. Patra J, Taylor B, Irving H, et al. Alcohol consumption and the risk of morbidity and mortality for different stroke types - a systematic review and meta-analysis. BMC Public Health. 2010;10.

54. Baliunas DM, Taylor BM, Irving HM, et al. Alcohol as a risk factor for type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2009;32(11):2123.

55. Rehm J, Taylor B, Mohapatra S, et al. Alcohol as a risk factor for liver cirrhosis: A systematic review and meta-analysis. Drug Alcohol Rev. 2010;29(4):437-45.

56. Corrao G, Bagnardi V, Zambon A, et al. A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med. 2004;38(5):613-9.

57. Physical Activity Guidelines Advisory Committee. Physical Activity Guidelines Advisory Committee Report. Washington, DC: U.S. Department of Health and Human Services, 2008.

BMJ Open

58. Blondell SJ, Hammersley-Mather R, Veerman JL. Does physical activity prevent cognitive decline and dementia?: A systematic review and meta-analysis of longitudinal studies. BMC Public Health. 2014;14(1):510.

FIGURES

Figure 1 Projected trends in the probability of dying prematurely from non-communicable disease for the WHO risk factor target scenarios.

Figure 2 Non-communicable disease deaths and YLDs that are averted or delayed between 2010 and 2025, for the combined risk factor target scenario. (Note: the small increase in COPD YLDs is due to a shift in the age distribution of the population, primarily as a result of reductions in CHD and stroke mortality, and does not reflect an increase in COPD rates).

Figure 3 DALYs averted for the WHO risk factor target scenarios.


Figure 4 DALYs averted for the combined WHO risk factor target scenario and the ideal risk reduction scenario. targets

SUPPORTING DOCUMENTS

Appendix 1: Calculating the combined effect of meeting all risk factor targets


Appendix 2: Ideal risk scenario results

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml




BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright.


Projected trends in the probability of dying prematurely from non-communicable disease for the WHO risk factor target scenarios. Figure 1 928x1164mm (96 x 96 DPI)




Non-communicable disease deaths and YLDs that are averted or delayed between 2010 and 2025, for the combined risk factor target scenario. (Note: the small increase in COPD YLDs is due to a shift in the age distribution of the population, primarily as a result of reductions in CHD and stroke mortality, and does not reflect an increase in COPD rates).

Figure 2 945x1101mm (96 x 96 DPI)





BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright



DALYs averted for the combined WHO risk factor target scenario and the ideal risk reduction scenario Figure 4 943x625mm (96 x 96 DPI)

For the combined risk factor target scenario the population impact fractions (PIFs) for coronary heart disease (CHD) and stroke were calculated multiplicatively from the individual PIFs for physical activity (PA), body mass index (BMI), blood pressure (BP), diabetes, alcohol and tobacco.

$$PIF_{Combined} = 1 - (1 - PIF_{BP}) \times (1 - PIF_{Diab}) \times (1 - PIF_{PA}) \times (1 - PIF_{BMI}) \times (1 - PIF_{Alc}) \times (1 - PIF_{Tob})$$

Figure 1 shows our conceptual model of the relationships between the risk factor targets and CHD, and Table 1 summarises the methods for calculation of the individual PIFs via the different pathways shown in Table 1. Notes below the table provide further detail on methods used to prevent double-counting of effects.

Figure 1 The modelled relationships between the WHO risk factor targets and CHD (NB. an identical process was used to estimate the combined risk factor effect on stroke.)




Table 1 Methods for the calculation of population impact fractions (PIFs) for the combined risk factor scenario

PIF	Cal	lculations	Sources	
PIF _{BP}	1. 2.	Calculate the full PA target effect on BP (i.e. directly and via BMI) Calculate the remaining BMI target effect on BP (i.e. the BMI effect	Cornelissen et al[Neter et al[2]	1]
	3.	excluding PA – see Note 1 below) Calculate the Salt target effect on BP	He et al[3] Prospective	Studies
	4.	Sum the effects on BP from steps 1 to 3, and calculate the CHD/Stroke PIF	Collaboration[4]	
	5. <i>PIF</i>	Calculate the CHD/Stroke PIF for the Hypertension target effect T_{BP} = the biggest of the PIFs calculated in steps 4 and 5		
PIF _{Diab}	1.	Calculate the full PA target effect on Diabetes (i.e. directly and via BMI), using RR adjusted for BMI	Wahid et al Unde Prospective Collaboration[5]	r review Studies

	 Calculate the remaining BMI target effect on Diabetes (i.e. the BMI effect excluding PA – see Note 1 below), using RR adjusted for PA (using adjustment estimate) 	Cobiac et al[6] (adjustment estimate) Peters et al[7,8]
	 Sum the effects on Diabetes from steps 1 and 2, and calculate the CHD/Stroke PIF 	
	4. Calculate the CHD/Stroke PIF for the Diabetes target effect <i>PIF_{Diab}</i> = the biggest of the PIFs calculated in steps 4 and 5	
PIF _{PA} (excluding effects via BP and Diabetes)	PIF_{PA} = PIF calculated for the direct PA using RR CHD/Stroke estimates (see Note 2 below)	Wahid et al Under review Health Survey for England 2012[9] Global Burden of Disease[10]
PIF _{BMI} (excluding effects via BP and Diabetes)	<i>PIF_{BMI}</i> = PIF calculated for the direct BMI using RR CHD/Stroke estimates (see Note 2 below)	Prospective Studies Collaboration[5] Cobiac et al[6] (adjustment estimate) Health Survey for England (HSE) 2012[9] Global Burden of Disease (GBD)[10]
PIF _{Alc}	PIF_{Alc} = PIF calculated using RR CHD/Stroke estimates from meta-analyses	Shield et al[11] Patra et al[12]
PIF _{Tob}	PIF_{Tob} = PIF calculated using RR CHD/Stroke estimates from meta-analyses	Cancer Prevention Study II[13]

Note 1 – calculating the PA target effect on BMI

To prevent double-counting of effects of changes in physical activity and BMI in the combined scenario, we estimated the change in BMI that could be attributed to the physical activity changes. Change in body weight was estimated using energy balance equations described by Hall et al[14], assuming change in fat free mass remains constant as a proportion of change in body weight[15].

Resting energy expenditure, a component of the energy balance calculations, was estimated from regression models derived by Mifflin et al[16] from a subset of healthy subjects enrolled in a diet and heart disease study. Physical activity levels, also a component of the energy balance calculations, were estimated from the total MET hours spent in all activities over the day. We used FAO[17] estimates of energy costs for sleeping, personal care (dressing, showering), eating, cooking and sitting/sedentary activities (e.g. office work, selling produce, tending shop). Energy costs of time spent in all other activities, such as sports and fitness activities, occupational lifting, active travel and home activities (e.g. housework) were determined from responses to physical activity survey questions in the Health Survey for England[9] and the Physical Activity Compendium[18]. We assumed that the increase in physical activity from reaching the WHO target, if it was to be sustained in the population, would need to result from a reduction in time spent sitting/sedentary rather than in time spent on sleeping, personal care, eating or cooking.

We calculated change in body weight from meeting the physical activity target by solving the energy balance equations using least squares and the generalised reduced gradient nonlinear method of optimisation in Excel. We then calculated change in BMI using height data from the Health Survey for England. From this we could distinguish the *remaining* BMI effect (i.e. the proportion of the BMI target effect that is not attributable to achieving the PA target).

Note 2 – calculating RRs for pathways not mediated by BP or Diabetes

To calculate the PIF_{PA} and PIF_{BMI} components of the combined PIF equation, we needed to know relative risks of CHD and Stroke associated with changes in PA and BMI that would *not* be mediated by either diabetes or BP (since the mediated contributions would already be counted in the PIF_{Diab} and PIF_{BP} calculations). Since we did not have published estimates of these RRs, we derived them using an optimisation process in Excel, assuming that the fractions of the disease attributable to the risk factor via the direct and indirect pathways would have to sum to the total attributable fraction.

This process is illustrated in Figure 2, with physical activity as the risk factor, diabetes as the intermediate variable and CHD as the disease (pathway A is the unknown). Using optimisation, we determined what the relative risks for CHD (pathway A) would need to be so that the total fraction of CHD attributable to PA (pathway C) would be equal to the sum of the contributions from PA directly (pathway A) and from PA via diabetes (pathway B).

The optimisation was performed twice. First we used the PA-CHD RR (Wahid et al meta-analysis, adjusted for BMI), the diabetes prevalence (HSE) and CHD mortality (GBD 2010) to derive a PA-CHD RR that is not mediated by diabetes (but may be mediated by BP). Second, we used the 'partly-mediated' RR output from the first step, along with the BP distribution (HSE) and CHD mortality (GBD 2010) to derive a PA-CHD RR that is not mediated by either diabetes or BP. This was the RR used in the calculation of the *PIF*_{PA} for the combined analyses.

The same methods were used to solve for the relative risks of stroke; and the whole process was repeated with BMI as the risk factor, using BMI RR estimates of CHD and stroke (for pathway C) from the Prospective Studies Collaboration[5].





Figure 2 Conceptual diagram of the pathways between risk factor (physical activity), intermediate variable (diabetes) and disease (CHD) in the optimisation process.

References

- 1. Cornelissen VA, Fagard RH (2005) Effects of endurance training on blood pressure, blood pressure– regulating mechanisms, and cardiovascular risk factors. Hypertension 46: 667-675.
- 2. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM (2003) Influence of weight reduction on blood pressure a meta-analysis of randomized controlled trials. Hypertension 42: 878-884.
- 3. He FJ, Li J, MacGregor GA (2013) Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. BMJ: British Medical Journal 346.
- 4. Prospective Studies Collaboration (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. The Lancet 360: 1903-1913.
- 5. Prospective Studies Collaboration (2009) Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. The Lancet 373: 1083-1096.
- 6. Cobiac LJ, Vos T, Veerman JL (2010) Cost-effectiveness of Weight Watchers and the Lighten Up to a Healthy Lifestyle program. Australian and New Zealand Journal of Public Health 34: 240-247.
- 7. Peters SA, Huxley RR, Woodward M (2014) Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia 57: 1542-1551.
- Peters SA, Huxley RR, Woodward M (2014) Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775 385 individuals and 12 539 strokes. The Lancet 383: 1973-1980.
- 9. Joint Health Surveys Unit (2014) Health Survey for England 2013 (and previous editions). Leeds: Health and Social Care Information Centre.
- 10. Wang H, Dwyer-Lindgren L, Lofgren KT, Rajaratnam JK, Marcus JR, et al. (2013) Age-specific and sex-specific mortality in 187 countries, 1970–2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet 380: 2071-2094.
- 11. Shield KD, Parry C, Rehm J (2014) Chronic diseases and conditions related to alcohol use. Alcohol research: current reviews 35: 155.
- 12. Patra J, Taylor B, Irving H, Roerecke M, Baliunas D, et al. (2010) Alcohol consumption and the risk of morbidity and mortality for different stroke types a systematic review and meta-analysis. BMC Public Health 10.
- 13. Thun MJ, Apicella LF, Henley SJ (2000) Smoking vs other risk factors as the cause of smokingattributable deaths: confounding in the courtroom. Jama 284: 706-712.
- 14. Hall KD, Sacks G, Chandramohan D, Chow CC, Wang YC, et al. (2011) Quantification of the effect of energy imbalance on bodyweight. The Lancet 378: 826-837.
- 15. Heitmann BL, Garby L (2002) Composition (lean and fat tissue) of weight changes in adult Danes. The American journal of clinical nutrition 75: 840-847.
- Mifflin MD, St Jeor ST, Hill LA, Scott BJ, Daugherty SA, Koh Y (1990) A new predictive equation for resting energy expenditure in healthy individuals. The American journal of clinical nutrition 51: 241-247.
- 17. FAO (2001) Human Energy Requirements: Report of a Joint FAO/WHO/UNU Expert Consultation. Rome: Food and Agriculture Organization of the United Nations, World Health Organization, United Nations University.

18. Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett Jr DR, et al. (2011) 2011 Compendium , te of t of Physical Activities: a second update of codes and MET values. Medicine and science in sports and exercise 43: 1575-1581.

36/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright





36/bmjopen-2016-

	30-69 years			g 70+ years		
	Men	Women	Men $\stackrel{\texttt{P}}{\succeq}$	Women		
Deaths			Mien April Til 20			
Obesity	63,000 (46,000 to 80,000)	26,000 (13,000 to 39,000)	230,000 (170,000 to 280,000) .7	170,000 (120,000 to 230,000)		
Tobacco use	88,000 (72,000 to 100,000)	61,000 (51,000 to 70,000)	360,000 (290,000 to 430,000) 反	290,000 (230,000 to 340,000)		
Diabetes	19,000 (16,000 to 23,000)	7,800 (6,300 to 9,200)	98,000 (80,000 to 120,000)	96,000 (78,000 to 110,000)		
Raised blood pressure	24,000 (23,000 to 25,000)	9,300 (8,600 to 10,000)	98,000 (80,000 to 120,000)	98,000 (92,000 to 100,000)		
Salt intake	24,000 (23,000 to 25,000)	6,200 (5,900 to 6,500)	95,000 (91,000 to 99,000)	62,000 (59,000 to 64,000)		
Harmful alcohol use	6,800 (-31,000 to 45,000)	20,000 (-2,300 to 43,000)		72,000 (-170,000 to 320,000)		
Physical inactivity	10,000 (7,200 to 13,000)	3,700 (2,700 to 4,700)	-8,400 (-120,000 to 100,000)	42,000 (31,000 to 54,000)		
Combined scenario	190,000 (150,000 to 230,000)	94,000 (69,000 to 120,000)	یے. 800,000 (660,000 to 940,000) کچ	640,000 (460,000 to 810,000)		
YLDs (Thousands)			n. br			
Obesity	390,000 (320,000 to 470,000)	320,000 (250,000 to 390,000)	720,000 (570,000 to 860,000) o	640,000 (490,000 to 790,000)		
Tobacco use	770,000 (700,000 to 840,000)	860,000 (810,000 to 920,000)	1,300,000 (1,200,000 to 1,500,000)	1,500,000 (1,400,000 to 1,600,000		
Diabetes	620,000 (610,000 to 630,000)	510,000 (510,000 to 520,000)	1,100,000 (1,000,000 to 1,100,000)	990,000 (970,000 to 1,000,000)		
Raised blood pressure	75,000 (71,000 to 79,000)	51,000 (46,000 to 55,000)	170,000 (160,000 to 180,000) 🚊	130,000 (120,000 to 140,000)		
Salt intake	76,000 (72,000 to 79,000)	36,000 (34,000 to 37,000)	150,000 (150,000 to 160,000) کې	83,000 (80,000 to 87,000)		
Harmful alcohol use	-82,000 (-260,000 to 100,000)	-120,000 (-260,000 to 23,000)	-120,000 (-410,000 to 170,000	-180,000 (-450,000 to 80,000)		
Physical inactivity	69,000 (58,000 to 80,000)	60,000 (51,000 to 70,000)	140,000 (120,000 to 170,000) පු	130,000 (110,000 to 160,000)		
Combined scenario	1,600,000 (1,500,000 to 1,700,000)	1,500,000 (1,400,000 to 1,600,000)	2,900,000 (2,700,000 to 3,100,000)	2,800,000 (2,500,000 to 3,000,000		
NB. Values are mean and	95% uncertainty intervals.		Protected by copyright.			

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

Translating the World Health Organization 25x25 goals into a United Kingdom context: The PROMISE modelling study

Journal:	BMJ Open
Manuscript ID	bmjopen-2016-012805.R1
Article Type:	Research
Date Submitted by the Author:	24-Oct-2016
Complete List of Authors:	Cobiac, Linda J.; University of Oxford, The British Heart Foundation Centre on Population Approaches for Non-Communicable Disease Prevention, Nuffield Department of Population Health; University of Melbourne School of Population and Global Health, Centre for Health Policy Scarborough, Peter; University of Oxford, Department of Public Health
Primary Subject Heading :	Public health
Secondary Subject Heading:	Health policy, Epidemiology
Keywords:	PUBLIC HEALTH, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, PREVENTIVE MEDICINE



1	
2	
3	
2 3 4 5 6 7	
5	
6	
7	
1	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
10	
10	
19	
20	
21	
7 8 9 10 11 12 13 15 16 7 8 9 10 11 23 24 26 27 28 9 31 23 24 56 7 8 9 10 11 23 24 56 27 28 9 31 23 24 56 20 31 23 24 56 20 31 23 24 25 20 20 20 20 20 20 20 20 20 20 20 20 20	
23	
24	
25	
26	
27	
28	
20	
29	
30	
31	
32	
33	
34 35 36 37	
35	
36	
37	
38	
39	
40	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
- 50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
00	

Translating the World Health Organization 25x25 goals into a United Kingdom context: The PROMISE modelling study

4 Linda J Cobiac

Burden of Disease Epidemiology, Equity and Cost Effectiveness (BODE3) Programme, University of
Otago, Wellington, New Zealand

7 British Heart Foundation Centre on Population Approaches for Non-Communicable Disease
8 Prevention, Nuffield Department of Population Health, University of Oxford, Old Road Campus,
9 Headington, Oxford, OX3 7LF, UK

10

3

11 Peter Scarborough

- 12 British Heart Foundation Centre on Population Approaches for Non-Communicable Disease
- 13 Prevention, Nuffield Department of Population Health, University of Oxford, Old Road Campus,
- 14 Headington, Oxford, OX3 7LF, UK

15

- 16 Corresponding author: Linda Cobiac linda.cobiac@dph.ox.ac.uk
- 17 Key words: non-communicable disease, prevention, modelling

18 Word count (main text): 4098

19

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright

1 ABSTRACT

- 2 Objective Model the impact of targets for obesity, diabetes, raised blood pressure, tobacco use,
- 3 salt intake, physical inactivity and harmful alcohol use, as outlined in the Global Non-Communicable
- 4 Disease Action Plan 2013-2020, on mortality and morbidity in the UK population.
- 5 Design Dynamic population modelling study
- 6 Setting UK population
- 7 Participants NA
- 8 Main outcome measures Mortality and morbidity (Years Lived with Disability) from non-
- 9 communicable diseases (NCDs) that are averted or delayed. Probability of achieving a 25% reduction
- 10 in premature mortality from NCDs by 2025 (current WHO target) and a 33% reduction by 2030
- 11 (proposed target).
- Results – The largest improvements in mortality would be achieved by meeting the obesity target and the largest improvements in morbidity would be achieved by meeting the diabetes target. The UK could achieve the 2025 and 2030 targets for reducing premature mortality with only a little additional preventive effort compared to current practice. Achieving all seven risk targets could avert a total of 300,000 deaths (95% uncertainty interval: 250,000 to 350,000) and 1.3 million Years Lived with Disability (1.2 million to 1.4 million) from NCDs by 2025, with the majority of health gains due to reduced mortality and morbidity from heart disease and stroke, and reduced morbidity from diabetes. Potential reductions in morbidity from depression and in morbidity and mortality from dementia at older ages are also substantial.
- Conclusions The global premature mortality targets are a potentially achievable goal for countries
 such as the UK that can capitalise on many decades of effort in prevention and treatment. High
 morbidity diseases and diseases in later life are not addressed in the Global NCD Action Plan and
 targets, but must also be considered a priority for prevention in the UK where the population is
 - ageing and the costs of health and social care are rising.

1 ARTICLE SUMMARY

- 2 Strengths and limitations of the study:
- The study combined functional demographic modelling of population forecasting, logistic
 regression modelling of 'business-as-usual' trends in NCD rates and NCD risk factors, and dynamic
 modelling of population health outcomes.
- We simulated the future changes in NCD mortality and morbidity that would occur: (1) with
- 7 'business-as-usual'; (2) if the UK could achieve the World Health Organization's risk factor
 8 reduction targets; and (3) if all NCD burden could be addressed.
- 9 We also estimated the probability that the UK would meet the current WHO target of a 25%
 10 reduction in premature mortality by 2025 and the new target of a 30% reduction by 2030.
- The modelling does not include known NCD risk factors for which there are no WHO 2025 targets
 (e.g. intake of fruits and vegetables, red and processed meats, transfats, etc.) and relies on
 limited evidence (e.g. observational studies) to simulate the relationships between risk factors
 and avoid the double-counting of target impacts on NCDs.
- Integrating projections of risk factor and disease trends with a population demographic model
 that stochastically forecasts trends in mortality, fertility and migration, is an important advance
 on existing global modelling methods.

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright

INTRODUCTION

Non-communicable diseases (NCDs) have been recognised as a major challenge for all nations in the 21st century, affecting people of all ages, gender, race and income level[2]. It is a burden that is in large part preventable; closely linked to a range of risky behaviours, including tobacco use, unhealthy diet, physical inactivity and harmful use of alcohol; risks that are themselves closely related to the societies and environments in which we live. In response to the United Nations declaration on addressing prevention and control of NCDs[2], the World Health Organization (WHO) developed a Global NCD Action Plan 2013-2020[3], which outlines global targets for improving prevalence of NCD risk factors (obesity, diabetes, raised blood pressure, tobacco use, salt intake, physical inactivity and harmful use of alcohol) with an overarching goal of achieving a 25% reduction in premature mortality from the four main NCDs (cardiovascular diseases, chronic respiratory diseases, cancers and diabetes) by the year 2025. Global modelling of the risk factor impacts on NCDs shows that premature mortality from the four main NCDs could be reduced globally by 22% in men and 19% in women, between 2010 and 2025, if the targets could be achieved[4].

It is the responsibility of individual countries to initiate actions to achieve the targets, and regularly measure and review national progress[5]. However, it is not clear to what extent the NCD and risk factor targets should guide priorities for action or to what extent progress will reflect a nation's improvement in health. While the four main NCDs are responsible for 87% of all NCD deaths worldwide, they only contribute to 57% of the ill health burden from NCDs[6]. There are also indications that targets for reducing tobacco use could be more ambitious[4]. These concerns are to some extent reflected in the new set of 'Sustainable Development Goals' (SDGs) and targets for 2030 that were adopted by United Nations world leaders in September 2015. The new health-related NCD goals aim to 'promote mental health and well-being' and to strengthen implementation of the WHO Framework Convention on Tobacco Control, alongside a revision of the premature

BMJ Open

mortality goal to a one-third reduction by 2030. In response to the SDGs, the WHO has signalled its
 intent to expand work on prevention of NCDs in 2016-17[7].

More information is needed about the impact of achieving the WHO risk factor targets on morbidity from NCDs and about the impact on a broad range of NCDs including mental health and neurological disorders. In a study funded by the Richmond Group of Charities[8], PROMISE, we have examined the implications of the WHO risk factor targets for priority setting in the UK. We modelled the impact of meeting the risk factor targets on morbidity and mortality from a wide range of NCDs, and examined whether the UK is likely to achieve a 25% reduction in premature mortality by 2025. In addition, in order to estimate how much of the potentially preventable portion of NCD burden could be addressed by the WHO targets, we evaluated an 'ideal risk reduction' scenario in which everyone in the UK achieves a normal weight, is physically active, non-smoking, without diabetes or raised blood pressure, has an ideal salt intake and does not drink alcohol at harmful levels. In this paper, we report on the results of this study, and consider the implications for setting future targets for risk reduction.

METHODS

We developed a dynamic model for simulating the effect of annual changes in risk factors on annual burden of non-communicable diseases in the UK. The modelling was carried out in two parts. First, we used historical data on risk factors in England to project trends in salt consumption, physical activity, alcohol consumption, smoking, body mass index, diabetes and blood pressure forward to 2025, and then used these trends to estimate the proportional impact on NCDs of achieving the 25x25 targets. Second, we developed a population and mortality forecast model which estimated business-as-usual projections of NCD morbidity and mortality to 2025. This was then used as the baseline to apply the proportional changes in disease, which were calculated in the first model to estimate the impact of achieving the WHO 25x25 targets and the ideal risk reduction on NCD mortality and morbidity.

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright

1 Risk factor projections model

Historical risk factor data were obtained from the Health Survey for England series[9]. This survey is conducted annually and collects data on a representative sample of community-living adults in England. Annual sample sizes are approximately 11,000 adults aged 18 and over. Data are collected on health behaviour (including diet, smoking, alcohol consumption and physical activity) using a standard questionnaire delivered and recorded by a trained interviewer. Anthropometric data, including body mass index and blood pressure, are recorded by a trained nurse. For the PROMISE project, we compiled a dataset (Stata Version 11) with data on the seven WHO targets from all surveys conducted between 1995 and 2012.

All risk factor projections were stratified by sex and broad age group (18 to 35; 36 to 55; 56+). For each stratum, following a method used for the UK Foresight 'Modelling future trends in obesity and their impact on health' project[10], we modelled the relationship between prevalence of the risk factor (p) and time (t) using the following equation (where *a* and *b* are model parameters):

$$p(\mathbf{t}) = \frac{1}{2} (1 + \tanh(a + b\mathbf{t}))$$

This relationship is convenient for modelling future projections, as it results in smooth changes over time that are constrained between minimum and maximum values of 0 and 100%. For each risk factor, we derived variables from the Health Survey for England dataset to match the risk factor definitions used for the WHO targets[11], and then used logistic regression to fit the above equation, with survey year providing the time variable. We then projected prevalence forward to 2025, assuming the equations hold until this time. Table 1 provides further details regarding projections for each of the seven risk factors.

21 Relative risks for the relationship between risk factors and diseases were taken from meta-analyses
22 of prospective studies (Table 2). In most cases, these were restricted to meta-analyses of cohort
23 studies, but in some cases meta-analyses that combined results from cohort studies and prospective

BMJ Open

case control studies (i.e. nested in cohort studies) were also included. With the exception of salt, the
relationship between the risk factors and disease outcomes was modelled directly, and preference
was given to relative risks that were adjusted for the most of the other risk factors. The effect of salt
on blood pressure levels was modelled using a meta-analysis of salt reduction trials[12], and then
the subsequent impact of blood pressure on disease was modelled as described above.

The evidence relating a link between the risk factors and both dementia and depression is less established than for the other disease outcomes. In some cases the mechanisms are unclear[13], or previous results investigating the relationship have been highly heterogeneous[14]. Meta-analyses of the relationship between risk factors and depression and dementia are often not based on analyses adjusted for other risk factors, increasing the risk of confounding[15]. For this reason, we present two sets of modelled results, for analyses that both include and do not include depression and dementia as outcomes.

13 Evaluating population impact fractions (PIFs)

The WHO targets and the ideal risk reduction scenarios for salt consumption, physical activity, alcohol consumption, smoking, body mass index, diabetes and blood pressure are described in Table 2. Our implementation of the WHO targets depended on whether the risk reductions were relative reductions (e.g. a 30% reduction in smoking) or absolute reductions (e.g. halt the rise in obesity). For relative reductions in the prevalence of a risk factor (smoking, blood pressure, alcohol, physical inactivity), the reduction was applied to the projected prevalence in every year between 2010 and 2025. For absolute reductions in the prevalence of a risk factor (obesity, diabetes), the target prevalence was assumed to be the actual prevalence in 2010. For relative reductions in a mean consumption of a risk factor (salt), the reduction was applied in every year between 2010 and 2025, and the standard deviation of the distribution for each age-sex stratum was assumed to remain constant (i.e. the entire distribution was shifted). The ideal risk reduction scenarios were based on definitions in the Global Burden of Disease study[16].

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright.

1	Table 1 Methods for the projection of risk factors.
_	

Risk factor	WHO definition	HSE years used	Comments
Overweight and obesity	Overweight: adults with BMI between 25 and 30. Obese: adults with BMI greater than 30.	All years between 1995 and 2012.	Five BMI categories were projected: ≤20; 20-≤25; 25-≤30; 30 ≤35; >35. The relationship between prevalence of each BM category and survey year was modelled separately Projections combined proportionately, in order to ensure the sum of all BMI categories was exactly 100% in any year.
Smoking	Prevalence of adult population currently using any tobacco product.	All years between 1995 and 2012.	The prevalence of current smoking and never smoking were projected. The prevalence of former smoking was assumed to be 100% - prevalence of never and current smokers.
Diabetes	Prevalence of raised blood glucose, or medication for raised glucose.	1998; 2003; 2006; 2009; 2010; 2011; 2012	We used prevalence of doctor-diagnosed diabetes. The WHC definition could not be used due to lack of representative data in England.
Blood pressure	PrevalenceofadultpopulationwithSBP≥140mmHgorDBP≥90mmHg.	All years between 1995 and 2012.	Prevalence of raised blood pressure projected. To estimate health impact of raised blood pressure, relative risks are based on median SBP of age-sex-raised blood pressure groups in HSE2012.
Alcohol	Prevalence of heavy episodic drinking (consuming ≥60g alcohol on a single occasion at least monthly)	All years between 1998 and 2012.	Three alcohol categories were projected: abstainers (<1g alcohol per week); non-harmful drinkers; harmful drinkers Projections were combined proportionately, in order to ensure the sum of all alcohol categories was exactly 100% ir any year. Relationships between alcohol and disease outcomes were based on difference in weekly alcoho consumption between alcohol groups, estimated using the HSE2012. A dummy variable was included in regression analyses to isolate the impact of changes in alcoho measurement in the HSE in 2006.
Physical inactivity	Prevalence of physical inactivity (less than 150 minutes of moderate- intensity activity per week, or equivalent).	1997; 1998; 2003; 2004; 2006; 2008; 2012	Three physical activity categories were projected: sedentary (≤0.2METh/d); not sedentary, but inactive; active. Logistic regression models estimated the trend in the prevalence of first two groups combined, and we separated between these two groups based on proportion of adults in HSE2012. The prevalence of activity was assumed to be 100% - prevalence of inactivity. Data between 1997 and 2012 were available or a consistent measure of inactivity, but only HSE2012 measured inactivity equivalent to the WHO definition Regression models were based on the consistent measure o inactivity then adjusted according to the difference in the two measures recorded in HSE2012. The risk relationship between physical activity and disease outcomes based or difference in amount of physical activity (METh/d) between physical activity categories, estimated using HSE2012 data.
Salt (mediated by blood pressure)	Mean population intake of salt.	2008; 2009; 2010;2011*	National Diet and Nutrition Survey urinary analyses data used to assess trends by age-sex groups. No trends apparent, so projections assume no change from current mear consumption levels. Mean and standard deviations used to generate normal distributions of salt consumption, which were converted into salt-related blood pressure using the prevalence of normotensives and hypertensives derived from the blood pressure projections, and parameters drawn from meta-analyses of salt reduction trials.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

obesityObese: adults with BMI greater than 30. WHO target: Halt the rise in obesity. Ideal target: Everyone normal weight (BMI 20-25; median 22)Cirrhosis[17]; Colorectal Kidney cancer[17]; Breast ideaese[17]; Kidney cancer[17]; Breast obesity Depression[19]; Demential Operssion[19]; Demential Operssion[20]; Dem Demential(26]DiabetesPrevalence of doctor-diagnosed diabetes. WHO target: Halt the rise in diabetes. WHO target: No prevalence of diabetesCHD[27]; Stroke[28]; Dep Dementia[30]Blood pressurePrevalence of adult population with SBP2140mmHg or DEPS90mmHg. WHO target: 25% relative reduction in raised blood pressure. Ideal target: No prevalence of raised blood pressure. Ideal target: No consumption. WHO target: 10% relative reduction. Mouth cancer[36]; Breast Oesophagus cancer[36]; Deressin[35]; Liver Mouth cancer[36]; Physical inactivityPrevalence of physical inactivity (less than 150 minutes of moderate-intensity activity per week, or equivalent). WHO target: 10% relative reduction. Ideal target: No relative reduction. Ideal target: Were neduction. Ideal target: 10% relative reduction. Ideal target: Were neduction. Ideal target: Were reduction. Ideal target: 10% relative reduction. Ideal target: 10% relative reduction. Ideal target: Were neduction. Ideal target: Were neduction. Ideal target: Were neduction. Ideal target: Were neduction. Ideal target: We	obesityObese: adults with BMI greater than 30. WHO target: Everyone normal weight (BMI 20-25; median 22)Cirrhosis[17]; Colorectal ca Kidney cancer[17]; Breast ca cancer[18]; cancer[17]; Hypertensive disease[17]; Kidney dis Depression[19]; Dementia[2]SmokingPrevalence of adult population currently using any tobacco product.COPD[21]; CHD[21]; SI Diabetes 20% relative reduction. Ideal target: 30% relative reduction. Ideal target: No current or past use of tobacco Bladder cancer[23]; Cenvic cancer[23];	Risk factor	Risk definitions and targets	Modelled NCD outcomes
tobacco product. WHO target: 30% relative reduction. Ideal target: No current or past use of tobaccoDiabetes[22]; Cesophagus cancer[23]; Stomach cance cancer[23]; Stomach cance cancer[23]; Cervix. Bladder cancer[23]; Dep Dementia[26]DiabetesPrevalence of doctor-diagnosed diabetes. WHO target: Halt the rise in diabetes. Ideal target: No prevalence of diabetesCHD[27]; Stroke[28]; Dep Dementia[30]Blood pressurePrevalence of adult population with SBP≥140mmHg or DBP≥90mmHg. WHO target: 25% relative reduction in raised blood pressure.CHD[31]; Stroke[31] heart disease[32]; Diver Othout cancer[35]; Liver (CHD[32]; Stroke[33]; Hi heart disease[32]; Diver Mouth cancer[36]; cancer[36]; Breast Oesophagus cancer[36]AlcoholPrevalence of heavy episodic drinking (consuming per capita consumption. WHO target: 10% relative reduction. deal target: No consumption of alcohol of moderate-intensity activity per week, or equivalent). WHO target: 10% relative reduction. Ideal target: Everyone physical inactivity per week, or equivalent). WHO target: 30% relative reduction. Ideal target: Keryone physical virieCHD[12, 31]; Stroke[12, 31 Depression[38]; Dementia] Depression[38]; Dementia] Depression[38]; Dementia]Salt (mediated by blood pressure)Mean population intake of 1000mg/dayCHD[12, 31]; Stroke[12, 31 Stroke[12, 31]NB. CHD: Coronary Heart Disease; COPD: Chronic Obstructive Pulmonary Disease. * Wahid et al. In press American Heart Association.CHD2Using the disease projections and the relative risk estimates, we calculated PIFs for each disease-	tobacco product. WHO target: 30% relative reduction. Ideal target: No current or past use of tobaccoDiabetes[22]; Lung ca Cancer[23]; Stomach cancer[24]; Pancreas ca Kidney cancer[23]; Cervix ca Bladder cancer[23]; Depret Dementia[26]DiabetesPrevalence of doctor-diagnosed diabetes. WHO target: Halt the rise in diabetes. UHO target: No prevalence of diabetesCHD[27]; Stroke[28]; Depret Dementia[30]Blood pressurePrevalence of adult population with SBP2140mmHg or DBP290mmHg. WHO target: 25% relative reduction in raised blood pressure. Ideal target: No prevalence of raised blood pressureCHD[31]; Stroke[31]AlcoholPrevalence of heavy episodic drinking (consuming per capita consumption. WHO target: 10% relative reduction. Ideal target: No consumption of alcoholCHD[32]; Stroke[33]; Hup heart disease[32]; Diat Cirrhosis[35]; Liver ca cancer[36]; Derest ca cancer[36]; Derest ca cancer[36]; Derest ca cancer[37]; Colorectal ca cancer[37]; Colorectal ca cancer[38]; Dementia[30]Physical inactivityPrevalence of physical inactivity (less than 150 minutes of moderate-intensity activity per week, or equivalent). WHO target: 10% relative reduction. Ideal target: Rean intake of salt. WHO target: 20% celative reduction. Ideal target: 20% celative reduction. Ideal target: 20% celative reduction. Ideal target: 30% celative reduction. <br< td=""><td>0</td><td>Obese: adults with BMI greater than 30. WHO target: Halt the rise in obesity. Ideal target: Everyone normal weight (BMI 20-25;</td><td>cancer[17]; Hypertensive</td></br<>	0	Obese: adults with BMI greater than 30. WHO target: Halt the rise in obesity. Ideal target: Everyone normal weight (BMI 20-25;	cancer[17]; Hypertensive
Diabetes Prevalence of doctor-diagnosed diabetes. WHO target: Halt the rise in diabetes. Ideal target: No prevalence of diabetes CHD[27]; Stroke[28]; Depr Dementia[30] Blood pressure Prevalence of adult population with SBP≥140mmHg or DBP≥90mmHg. WHO target: 25% relative reduction in raised blood pressure. Ideal target: No prevalence of raised blood pressure CHD[31]; Stroke[31] Alcohol Prevalence of heavy episodic drinking (consuming ≥60g alcohol on a single occasion at least monthly) and per capita consumption. WHO target: 10% relative reduction. Ideal target: No consumption of alcohol CHD[32]; Stroke[33]; Hiver Mouth cancer[36]; Breast Oesophagus cancer[36] Physical inactivity Prevalence of physical inactivity (less than 150 minutes of moderate-intensity activity per week, or equivalent). WHO target: 30% relative reduction. Ideal target: Everyone physically active CHD[12, 31]; Stroke[12, 31] Salt (mediated by blood pressure) WHO target: 30% relative reduction. Ideal target: Mean intake of 1000mg/day CHD[12, 31]; Stroke[12, 31] NB. CHD: Coronary Heart Disease; COPD: Chronic Obstructive Pulmonary Disease. * Wahid et al. In press American Heart Association. CHD[12, stroke for each disease-in- active reduction in target set mean intake of 1000mg/day 3 Using the disease projections and the relative risk estimates, we calculated PIFs for each disease-in-	Diabetes Prevalence of doctor-diagnosed diabetes. WHO target: Halt the rise in diabetes. Ideal target: No prevalence of dubtes CHD[27]; Stroke[28]; Depression Dementia[30] Blood pressure Prevalence of adult population with SBP≥140mmHg or DBP≥90mmHg. WHO target: 25% relative reduction in raised blood pressure. Ideal target: No prevalence of raised blood pressure CHD[31]; Stroke[31] Alcohol Prevalence of heavy episodic drinking (consuming per capita consumption. WHO target: 10% relative reduction. Ideal target: No consumption of alcohol CHD[32]; Stroke[33]; Hyp 260g alcohol on a single occasion at least monthly) and per capita consumption. WHO target: 10% relative reduction. Ideal target: No consumption of alcohol CHD*; Stroke*; Diabetes* of moderate-intensity activity per week, or equivalent). WHO target: 10% relative reduction. Ideal target: torvorpe physically active CHD[12, 31]; Stroke[12, 31] Salt (mediated by blood pressure) Mean population intake of salt. WHO target: 30% relative reduction. Ideal target: Mean intake of 1000mg/day CHD[12, 31]; Stroke[12, 31] NB. CHD: Coronary Heart Disease; COPD: Chronic Obstructive Pulmonary Disease. * Wahid et al. In press, J American Heart Association. American disease-rise 4 factor relationship, in each age-sex stratum, in every year between 2010 and 2025. PIFs estimate th proportion of disease in a population that is removed under a counterfactual scenario (in this case)	Smoking	tobacco product. WHO target: 30% relative reduction.	Diabetes[22]; Lung canc Oesophagus cancer[23]; cancer[23]; Stomach cancer[23 cancer[24]; Pancreas canc Kidney cancer[23]; Cervix canc Bladder cancer[23]; Depressio
DBP≥90mmHg. WHO target: 25% relative reduction in raised blood pressure. Ideal target: No prevalence of raised blood pressure Alcohol Prevalence of heavy episodic drinking (consuming consumption) CHD[32]; Stroke[33]; Hi heart disease[32]; Di per capita consumption. WHO target: 10% relative reduction. Mouth cancer[36]; Liver Mouth cancer[36]; Physical inactivity Prevalence of physical inactivity (less than 150 minutes of moderate-intensity activity per week, or equivalent). CHD*; Stroke*; Diabete cancer[37]; Colorectal Depression[38]; Dementia] WHO target: 10% relative reduction. Ideal target: Everyone physically active CHD[12, 31]; Stroke[12, 31] Salt (mediated by blood pressure) Mean population intake of 1000mg/day CHD[12, 31]; Stroke[12, 31] NB. CHD: Coronary Heart Disease; COPD: Chronic Obstructive Pulmonary Disease. * Wahid et al. In press American Heart Association. 2 3 Using the disease projections and the relative risk estimates, we calculated PIFs for each disease-1	DBP≥90mmHg. WHO target: 25% relative reduction in raised blood pressure. Ideal target: No prevalence of raised blood pressure Alcohol Prevalence of heavy episodic drinking (consuming 260g alcohol on a single occasion at least monthly) and per capita consumption. WHO target: 10% relative reduction. Ideal target: No consumption of alcohol CHD[32]; Stroke[33]; Hyp heart disease[32]; Diat Cirrhosis[35]; Liver ca Mouth cancer[36]; Consumption of alcohol Physical inactivity Prevalence of physical inactivity (less than 150 minutes of moderate-intensity activity per week, or equivalent). WHO target: 10% relative reduction. Ideal target: Everyone physically active CHD*; Stroke*; Diabetes* cancer[37]; Colorectal ca Depression[38]; Dementia[3]; WHO target: 30% relative reduction. Ideal target: Everyone physically active Salt (mediated by blood pressure) Mean population intake of salt. Udeal target: Mean intake of 1000mg/day CHD[12, 31]; Stroke[12, 31] blood pressure) NB. CHD: Coronary Heart Disease; COPD: Chronic Obstructive Pulmonary Disease. * Wahid et al. In press, J American Heart Association. Namerican Heart Association. 2 Using the disease projections and the relative risk estimates, we calculated PIFs for each disease-rise factor relationship, in each age-sex stratum, in every year between 2010 and 2025. PIFs estimate th proportion of disease in a population that is removed under a counterfactual scenario (in this case	Diabetes	WHO target: Halt the rise in diabetes.	CHD[27]; Stroke[28]; Depression
Alcohol Prevalence of heavy episodic drinking (consuming ≥60g alcohol on a single occasion at least monthly) and per capita consumption. CHD[32]; Stroke[33]; He heart disease[32]; Di Cirrhosis[35]; Liver Mouth cancer[36]; Ideal target: 10% relative reduction. Ideal target: No consumption of alcohol Cancer[36]; Breast Oesophagus cancer[36] Physical inactivity Prevalence of physical inactivity (less than 150 minutes of moderate-intensity activity per week, or equivalent). CHD*; Stroke*; Diabete cancer[37]; Colorectal Depression[38]; Demential Depression[38]; Dementia	Alcohol Prevalence of heavy episodic drinking (consuming ≥60g alcohol on a single occasion at least monthly) and per capita consumption. CHD[32]; Stroke[33]; Hyp heart disease[32]; Diat Cirrhosis[35]; Liver capita consumption. WHO target: 10% relative reduction. Mouth cancer[36]; C Cancer[36]; Breast capes: of moderate-intensity activity per week, or equivalent). Physical inactivity Prevalence of physical inactivity (less than 150 minutes of moderate-intensity activity per week, or equivalent). CHD*; Stroke*; Diabetes* cancer[37]; Colorectal capersion[38]; Dementia[39] Salt (mediated by Mean population intake of salt. CHD[12, 31]; Stroke[12, 31] blood pressure) WHO target: 30% relative reduction. CHD[12, 31]; Stroke[12, 31] American Heart Association. 2 Using the disease projections and the relative risk estimates, we calculated PIFs for each disease-rise factor relationship, in each age-sex stratum, in every year between 2010 and 2025. PIFs estimate the proportion of disease in a population that is removed under a counterfactual scenario (in this case	Blood pressure	Prevalence of adult population with SBP≥140mmHg or DBP≥90mmHg. WHO target: 25% relative reduction in raised blood pressure.	CHD[31]; Stroke[31]
 of moderate-intensity activity per week, or cancer[37]; Colorectal pequivalent). WHO target: 10% relative reduction. Ideal target: Everyone physically active Salt (mediated by blood pressure) WHO target: 30% relative reduction. Ideal target: Mean intake of 1000mg/day NB. CHD: Coronary Heart Disease; COPD: Chronic Obstructive Pulmonary Disease. * Wahid et al. In press, American Heart Association. Using the disease projections and the relative risk estimates, we calculated PIFs for each disease-relative risk estimates, we calculated PIFs for each disease-relative risk estimates, we calculated PIFs for each disease-relative risk estimates. 	of moderate-intensity activity per week, or cancer[37]; Colorectal ca equivalent). WHO target: 10% relative reduction. Ideal target: Everyone physically active Salt (mediated by Mean population intake of salt. blood pressure) WHO target: 30% relative reduction. Ideal target: Mean intake of 1000mg/day NB. CHD: Coronary Heart Disease; COPD: Chronic Obstructive Pulmonary Disease. * Wahid et al. In press, J American Heart Association. Using the disease projections and the relative risk estimates, we calculated PIFs for each disease-rise factor relationship, in each age-sex stratum, in every year between 2010 and 2025. PIFs estimate th proportion of disease in a population that is removed under a counterfactual scenario (in this case	Alcohol	≥60g alcohol on a single occasion at least monthly) and per capita consumption. WHO target: 10% relative reduction.	heart disease[32]; Diabet Cirrhosis[35]; Liver canc Mouth cancer[36]; Cole cancer[36]; Breast canc
Salt (mediated by blood pressure) Mean population intake of salt. CHD[12, 31]; Stroke[12, 31]; St	Salt (mediated by blood pressure) Mean population intake of salt. WHO target: 30% relative reduction. Ideal target: Mean intake of 1000mg/day CHD[12, 31]; Stroke[12, 31] NB. CHD: Coronary Heart Disease; COPD: Chronic Obstructive Pulmonary Disease. * Wahid et al. In press, J American Heart Association. Namerican Heart Association. Using the disease projections and the relative risk estimates, we calculated PIFs for each disease-rise factor relationship, in each age-sex stratum, in every year between 2010 and 2025. PIFs estimate the proportion of disease in a population that is removed under a counterfactual scenario (in this case)	Physical inactivity	of moderate-intensity activity per week, or equivalent). WHO target: 10% relative reduction.	CHD*; Stroke*; Diabetes*; cancer[37]; Colorectal canc Depression[38]; Dementia[39]
 NB. CHD: Coronary Heart Disease; COPD: Chronic Obstructive Pulmonary Disease. * Wahid et al. In press, American Heart Association. Using the disease projections and the relative risk estimates, we calculated PIFs for each disease-relative risk estimates. 	 NB. CHD: Coronary Heart Disease; COPD: Chronic Obstructive Pulmonary Disease. * Wahid et al. In press, J American Heart Association. Using the disease projections and the relative risk estimates, we calculated PIFs for each disease-rist factor relationship, in each age-sex stratum, in every year between 2010 and 2025. PIFs estimate the proportion of disease in a population that is removed under a counterfactual scenario (in this case) 		Mean population intake of salt. WHO target: 30% relative reduction.	CHD[12, 31]; Stroke[12, 31]
3 Using the disease projections and the relative risk estimates, we calculated PIFs for each disease-	 Using the disease projections and the relative risk estimates, we calculated PIFs for each disease-rise factor relationship, in each age-sex stratum, in every year between 2010 and 2025. PIFs estimate the proportion of disease in a population that is removed under a counterfactual scenario (in this case) 	American Heart Asso	-	ase. * Wahid et al. In press, Jou
4 factor relationship, in each age-sex stratum, in every year between 2010 and 2025. PIFs estimate	5 proportion of disease in a population that is removed under a counterfactual scenario (in this case		rojections and the relative risk estimates, we calcula	ted PIFs for each disease-risk
		4 factor relationship,	in each age-sex stratum, in every year between 2010) and 2025. PIFs estimate the
5 proportion of disease in a population that is removed under a counterfactual scenario (in this ca	6 in the comparing where the WHO targets or ideal levels are achieved). We calculated DITE wing the	5 proportion of disea	se in a population that is removed under a counter	actual scenario (in this case,

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright

population in risk factor category *i* in the estimate year based on achieving the WHO or ideal risk
 reduction target, and *RR_i* is the relative risk for the disease in risk factor category *i*:

$$PIF = \frac{\sum_{i=1}^{k} p_i RR_i - \sum_{i=1}^{k} p'_i RR_i}{\sum_{i=1}^{k} p_i RR_i}$$

We present results separately for each risk factor (i.e. when only the single risk factor target is achieved) and in combination (i.e. if all risk factor targets are achieved). For the combined scenario, we multiplicatively combined PIFs for blood pressure, diabetes, physical activity, BMI, alcohol and tobacco:

 $PIF_{Combined} = 1 - (1 - PIF_{BP}) \times (1 - PIF_{Diab}) \times (1 - PIF_{PA}) \times (1 - PIF_{BMI}) \times (1 - PIF_{Alc}) \times (1 - PIF_{Tob})$ We adjusted for potential double-counting of risk factor effects on CHD and stroke where there are interdependencies in risks (e.g. physical activity affects CHD directly and via changes in BMI; BMI affects CHD directly and via changes in blood pressure). Figure 1 shows a conceptual model of the relationships between the risk factor targets for these diseases.

The effects of changes in alcohol and tobacco were assumed to be independent of each other and of all other risk factors. However, where risk factors were both mediating variables and the subject of WHO targets (blood pressure and diabetes), we took the larger of the effects. For example, we calculated the combined effects of meeting physical activity, BMI and salt targets on BP (assuming they are independent i.e. additive), we then calculated the effect of the hypertension target on BP, and took only the larger of these two effects. Similarly, we calculated the combined effect of meeting physical activity and BMI targets on diabetes (adjusting for the effects of physical activity on BMI), then estimated the effect of the diabetes target on diabetes prevalence, and took only the larger of the two effects. Further details on the methods for avoiding double counting are provided in Appendix 1.We calculated 95% uncertainty intervals for all PIFs, based on lognormal distributions for the relative risks and normal distributions for other variables as reported in the literature (e.g. effect of salt on blood pressure), using Monte Carlo analysis[40].

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 Disease projections model

The PIFs were applied to projected disease rates in a UK population and mortality forecast model in
order to estimate disease outcomes of meeting WHO targets. The model was built in R (version
3.1.2) using packages *demography* and *systemfit*.

The UK population was forecast out to 2025 based on historical demographic patterns. We used data from the period 1938 to 2010, obtaining population and mortality from the Human Mortality Database[41], fertility from the Human Fertility Database[42], and deriving net migration for the same time period, from these data. These demographic rates were smoothed using penalised regression splines. We then fitted functional demographic models[43] to mortality, fertility and migration rates from 1938 to 2010, and used these models to forecast future rates out to 2030. Finally, we simulated the population over time to 2030, using bootstrapping to estimate uncertainty in the population from the errors in the mortality, fertility and migration models.

For projecting disease-specific mortality, we developed regression models using methods described by Salomon and Murray[44] that ensure that disease-specific mortality projections are consistent with the projected all-cause mortality envelope. We obtained cause-specific mortality data from the WHO database[45], focusing on deaths coded using the most recent version of the International Classification of Diseases (ICD-10). ICD-10 was only adopted in the UK in 2001, which limited the analyses to only 10 years of past data points. Including deaths coded using the preceding ICD-9 version, increased the years of available data back to 1980, but although we applied translations from ICD-9 to ICD-10[46], there remained visible anomalies in the data before/after the change in coding for some disease. Concerned that this could lead to incorrect predictions of trends, we therefore restricted the analyses to the ICD-10 coded data, but broadened our data set to include data from all EU countries, which have similar high income and low mortality profile, and included GDP per capita into the model as an explanatory variable.

Page 12 of 42

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright

BMJ Open

Deaths coded to heart failure (I50) were redistributed to the primary causes (e.g. coronary heart disease (CHD), hypertensive heart disease, COPD and chronic kidney disease)[47]. Deaths were grouped into three age groups: <35, 35-64 and 65+. For each age group, we determined countryspecific mortality for each risk factor-related disease, and all other diseases, as a proportion of all-cause mortality in each country. Using methods described by Salomon and Murray[44] we specified a multivariate normal model for the log of the ratios of each cause fraction to the cause fraction for all other diseases, using the log of all-cause mortality rate and GDP per capita[48] as explanatory variables. We then derived parameter values for the disease projections models, for each age group, using seemingly unrelated regression[49].

10 To project disease rates forward in time for the UK, we applied the mortality projections from our 11 population forecasts and GDP projections from the World Bank[48] in the disease projections 12 models, to determine the annual average change in disease rates for the UK out to 2030.

13 Evaluating disease burden

To determine the future changes in population if the WHO or ideal risk reduction targets are achieved we first calculated the new population mortality, using the PIFs to determine future changes in mortality from the NCDs. We then re-simulated the future population out to 2030, using the new rates of mortality, but assuming no change in forecasts of fertility and migration.

Effects on premature mortality were estimated as the change in probability of death from NCDs between the ages of 30 and 69[3]. As was done in the global modelling of the WHO NCD reduction targets[4], our estimate was unconditional, in that it excluded deaths from other causes (e.g. injuries), but due to the broader range of diseases of interest in the PROMISE study, we included all NCDs, rather than restricting the analysis to the four main NCD groups (cardiovascular, cancer, diabetes and chronic respiratory diseases).

We defined the morbidity burden associated with non-communicable diseases as the reduction in
one year of life at full health. This was calculated at each age and sex, from Global Burden of Disease

BMJ Open

estimates of prevalent years lived with disability (YLDs). We included a business-as-usual trend in
morbidity if there had been a significant change in Global Burden of Disease YLD estimates between
1990 and 2010. For diabetes and depression, we estimated a morbidity effect of achieving the WHO
targets, which we estimated using the PIFs for these diseases in the same way that the PIFs were
applied to mortality for all other NCDs.

RESULTS

With a continuation of current trends in mortality, fertility and migration, the number of 30 to 69 year olds in the UK population is expected to increase from around 32.5 million in 2010 to 33.4 million in 2025, with the proportion of the whole population aged over 70 rising from 12.5% in 2010 to 16.2% by 2025. With business-as-usual, the probability of premature mortality (30-69 years) from non-communicable diseases among men is expected to fall from 17.6% in 2010 to 13.7% in 2025 (Figure 2). This equates to a relative reduction of 22%, which is just short of the WHO 25% reduction target. Premature mortality among women, is expected to reach the WHO target, falling from 11.9% in 2010 to 8.9% in 2025 (Figure 2), which equates to a relative reduction of 25%. If we assume trends in risk factors and diseases continue to 2030, the outcomes follow the same pattern, with men (30%) falling short of the 33% reduction target and women (33%) just reaching it.

There is added benefit from achieving the WHO 2025 behavioural risk factor targets (Table 3), which ranges from an added relative reduction of 0.1% (reduced physical inactivity) to 2.3% (rise in obesity halted). The combined effect of achieving all seven risk factor targets (relative reduction of 6.1% for men and 3.0% for women) is sufficient for both men and women to reach the 25% premature mortality reduction target by 2025 (Figure 2). Achieving the WHO targets would, however, achieve only a quarter of what could potentially be achieved for men and less than a fifth of what could potentially be achieved for women. BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright

Achieving all seven behavioural risk factor targets would avert a total of 300,000 deaths (at all ages) and 1.3 million YLDs from the reductions in related NCDs (excluding effects on depression and dementia) between 2010 and 2025 (Table 4). The majority of improvements in mortality are due to fewer deaths from CHD and stroke, while the majority of improvements in morbidity are due to reduced rates of diabetes, CHD and stroke (Figure 3). Figure 3 also shows that there is potentially a substantial additional gain in morbidity from reduced rates of depression in the 30-69 and 70+ age groups; and substantial additional gains in both morbidity and mortality from reduced rates of dementia in 70+ year olds.

9 The results demonstrate that, for the UK, achieving the obesity target will result in the biggest 10 overall impact on mortality and morbidity (Figure 4). Halting the rise in diabetes and achieving a 30% 11 reduction in salt intake would also achieve a large impact on NCD mortality, and reducing tobacco 12 consumption by 30% would have a large impact on morbidity.

Over time, achieving the combination of WHO risk factor targets would address an increasing proportion of the health that could potentially be gained if everyone could adjust their risk behaviour to ideal levels in 2010 (Figure 5 and Appendix 2 for deaths and YLDs averted under the ideal risk scenario). Taking both morbidity and mortality into account, by 2025, 29% of the health gain would be achieved for men and 26% for women. If we assume trends in risk factors and diseases continue beyond 2025, the proportions would reach 35% for men and 33% for women by 2030.

	WHO risk factor targets		Ideal ris	Ideal risk reduction		Proportion of ideal risk addressed by meeting WHO target	
	Men	Women	Men	Women	Men	Women	
Business-as-usual	22%	25%					
Additional reduction if a	chieving risk factor target	ts or ideal risk scenario:					
Obesity	2.3% (1.6% to 2.9%)	1.1% (0.3% to 1.9%)	7.9% (5.9% to 9.8%)	4.8% (2.6% to 7.1%)	29%	24%	
Tobacco use	0.6% (0.6% to 0.7%)	0.6% (0.6% to 0.7%)	12.1% (10.1% to 14.0%)	9.7% (8.2% to 11.1%)	5%	7%	
Diabetes	1.4% (1.2% to 1.7%)	0.7% (0.6% to 0.8%)	2.7% (2.2% to 3.2%)	1.4% (1.2% to 1.7%)	53%	51%	
Raised blood pressure	0.4% (0.4% to 0.4%)	0.2% (0.2% to 0.2%)	1.6% (1.6% to 1.7%)	0.7% (0.7% to 0.8%)	25%	25%	
Salt intake	0.8% (0.8% to 0.9%)	0.3% (0.3% to 0.3%)	2.1% (2.0% to 2.2%)	0.7% (0.7% to 0.8%)	39%	40%	
Harmful alcohol use*	0.6% (0.4% to 0.8%)	0.3% (0.22% to 0.5%)	0.9% (-4.6% to 4.0%)	3.2% (-1.08% to 6.9%)	62%	11%	
Physical inactivity	0.1% (0.08% to 0.1%)	0.1% (0.0% to 0.1%)	1.1% (0.81% to 1.4%)	0.6% (0.4% to 0.7%)	10%	10%	
Combined scenario	6.5% (5.4% to 7.5%)	3.2% (2.2% to 4.1%)	26.2% (21.9% to 29.7%)	18.4% (14.3% to 22.2%)	25%	17%	

NB. Values are mean and 95% uncertainty intervals. * Low-level consumption of alcohol is associated with a decreased risk of some diseases (e.g. CHD, hypertensive heart disease and diabetes), which partly counter the modelled health benefits of abstaining from alcohol.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

	30-	69 years	70+ years		
	Men	Women	Men	Women	
Deaths					
Obesity	13,000 (8,900 to 17,000)	4,500 (500 to 8,600)	47,000 (34,000 to 60,000)	26,000 (11,000 to 40,000)	
Tobacco use	5,100 (4,800 to 5,400)	4,300 (4,100 to 4,400)	14,000 (13,000 to 15,000)	15,000 (14,000 to 15,000)	
Diabetes	7,200 (5,900 to 8,600)	2,500 (2,000 to 2,900)	38,000 (30,000 to 45,000)	32,000 (26,000 to 38,000)	
Raised blood pressure	5,700 (5,400 to 6,100)	2,300 (2,100 to 2,500)	25,000 (24,000 to 26,000)	23,000 (22,000 to 24,000)	
Salt intake	9,000 (8,700 to 9,400)	2,500 (2,400 to 2,600)	38,000 (37,000 to 39,000)	26,000 (25,000 to 27,000)	
Harmful alcohol use	4,900 (3,000 to 6,900)	2,000 (1,200 to 2,800)	11,000 (7,100 to 16,000)	6,100 (800 to 11,000)	
Physical inactivity	920 (660 to 1,200)	320 (240 to 400)	4,300 (3,200 to 5,400)	3,900 (2,800 to 4,900)	
Combined scenario	38,000 (32,000 to 44,000)	13,000 (8,500 to 17,000)	150,000 (130,000 to 170,000)	99,000 (79,000 to 120,000)	
YLDs					
Obesity	79,000 (66,000 to 93,000)	50,000 (38,000 to 63,000)	150,000 (120,000 to 170,000)	98,000 (66,000 to 130,000)	
Tobacco use	20,000 (20,000 to 21,000)	25,000 (25,000 to 26,000)	27,000 (26,000 to 28,000)	37,000 (36,000 to 38,000)	
Diabetes	190,000 (190,000 to 190,000)	160,000 (160,000 to 160,000)	330,000 (320,000 to 340,000)	290,000 (290,000 to 300,000)	
Raised blood pressure	18,000 (17,000 to 19,000)	12,000 (11,000 to 13,000)	40,000 (38,000 to 42,000)	31,000 (29,000 to 33,000)	
Salt intake	29,000 (28,000 to 30,000)	14,000 (14,000 to 15,000)	60,000 (57,000 to 62,000)	34,000 (33,000 to 36,000)	
Harmful alcohol use	6,200 (-18,000 to 30,000)	-280 (-8,700 to 8,100)	14,000 (-25,000 to 53,000)	3,100 (-12,000 to 18,000)	
Physical inactivity	6,200 (5,300 to 7,000)	5,500 (4,700 to 6,200)	13,000 (11,000 to 15,000)	13,000 (11,000 to 14,000)	
Combined scenario	260,000 (240,000 to 280,000)	200,000 (190,000 to 210,000)	480,000 (430,000 to 520,000)	370,000 (350,000 to 400,000)	

NB. Values are mean and 95% uncertainty intervals..

 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright.

BMJ Open

DISCUSSION

There have been considerable achievements in addressing the risks for non-communicable disease in the UK over the last three decades. Although prevalence of obesity and diabetes have risen, initiatives such as increasing access to blood pressure-lowering drugs, reducing salt in processed foods, and strengthening tobacco control, have all contributed to the reduction in these risk factors over time. These changes in lifestyle behaviours, along with advances in treatment, have contributed to the reduction in non-communicable diseases that we observed. Our projections show that if these trends continue, there is likely to be a substantial further reduction in NCD burden by 2025, which will see the UK very nearly reach the current WHO target of 25% reduction in premature mortality and very likely reach the proposed 30% reduction by 2030.

11 It will be critical that past investments in prevention (and treatment) are sustained so that the UK 12 does not lose the momentum built over previous decades. Preventive efforts must also be increased 13 if the UK is to meet the 2025 target. While the targets do provide a worthwhile objective, a further 14 two-thirds of the preventable NCD burden could potentially be reduced with an even more ambitious 15 prevention program in the future.

Although current WHO targets focus on premature mortality, our modelling predicted substantial added benefits from reduced NCD morbidity, particularly at older ages. Around 16% of Government spending in the UK is allocated to health, which is high compared to other European countries[50]. The large reductions in NCD burden, particularly for CHD, stroke, diabetes, depression and dementia, would help reduce these costs. The social and economic burden of diseases such as depression and dementia is also high. Depression for example is associated with increased workplace absenteeism and reduced productivity[51], and dementia is associated with substantial social care costs[52]. In 2012 the cost of health and social care services for dementia patients in the UK was greater than the costs of CHD, stroke and cancer care combined[52].

Unfortunately the drivers of mental and neurological disorders, despite a high global burden, are
poorly understood[37]. Further research is needed to strengthen the epidemiological evidence of the

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright

links between lifestyle risks and prevention of diseases, such as depression and dementia, and to better understand how prevalence of these diseases may in turn increase risk of other NCDs. In the UK, funding for dementia and mental health research is low in comparison to the size of the burden[52, 53]. However, a review of costs and burden of mental and neurological disorders in the EU estimated that the return on investment in research would be highly favourable when taking the full cost to society into account[54].

Cost-effectiveness analysis can be used to identify which interventions will provide best value-for-money. Modelling of interventions for improving diet and body mass in England, suggest that fiscal measures and regulation may be more cost-effective than more individually targeted approaches such as physician counselling and worksite programs[55], which is consistent with findings from modelling studies in comparable high income countries such as Australia[56, 57] and New Zealand[58]. But further work is needed to identify the most effective and cost-effective interventions for addressing a wider range of risk factor targets in the UK, including a number of dietary risks associated with a high NCD burden that are not included in the WHO targets (e.g. fruits and vegetables, fats and cholesterol[37]). Modelling is also needed to better understand and quantify the health impacts of underlying drivers of change, such as global marketing and trade, the design of urban environments and climate change.

The WHO's inclusion of dietary risk factors as targets in the Global NCD Action Plan was minimal, given the high level of attributable NCD burden[37]. For example, while a 30% reduction target was set for salt intake, no targets were defined for reducing intake of transfats, red and processed meats or sugar-sweetened beverages, or increasing intake of fibre, whole grains, fruits and vegetables. The omission of these risk factors does mean that our study and previous global modelling estimates[4] are likely to have underestimated the potential for reduction in premature mortality from NCDs.

To model the impact of changing risk factors on NCDs, it is necessary to draw on a wide variety of different levels of evidence to calculate the dependencies between risk factors and avoid doublecounting of outcomes. For example, to calculate impacts on BMI from changes in physical activity we

BMJ Open

relied on models of human energy-balance derived by Hall et al[59]; to calculate impacts on blood pressure levels from changes in salt intake, we used measures from meta-regression of randomised controlled trials of blood pressure reduction; and to determine dose-response relationships between risk factors and diseases we drew on a variety of meta-analyses of observational studies. While most studies adjust for potential confounding factors (e.g. age, sex, smoking) it is impossible to rule out residual confounding from missing or poorly measured explanatory variables. In addition, where there are multiple pathways between a risk factor and disease (e.g. there is risk of CHD from physical inactivity directly and indirectly via diabetes) we have estimated the relative risks for the two pathways from studies of the risk for the pathways combined and the prevalence of the risk factors (see Note 2 in Appendix 1). These approximations are necessary in the absence of large, long-term studies that measure and adjust for all possible risks simultaneously. Consequently, it is likely that there is greater uncertainty in our results than is reflected in the uncertainty intervals we have estimated.

This modelling study contributes to the evidence about the potential impact of changes in risk factor prevalence, but to implement change evidence is needed on interventions designed to tackle behavioural risk factors. The relative magnitude of health gain associated with the WHO risk factor targets is not necessarily a good guide for setting priorities for intervention. The apparently smaller benefits of addressing physical inactivity and harmful alcohol use, for example, are in large part because the WHO targets are relatively modest. The modelling of alcohol targets also does not capture any benefits from reduced injury rates, which fall outside of the NCD focus of the WHO targets. In addition, the modelling of some risk factors was limited by the available data (e.g. self-reported physical activity) and WHO definitions (e.g. prevalence of hypertension rather than the full distribution of blood pressure). In addition, past decades of successful intervention in the UK (e.g. blood pressure lowering drugs, tobacco taxes, smoking cessation programs) has seen the prevalence of high blood pressure and prevalence of smoking decline, so that the WHO targets (25% relative reduction in high BP and 30% relative reduction in smoking) are relatively less beneficial than the

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright

1 targets to halt the rise in prevalence of obesity and diabetes, both of which are rising steeply in the

2 UK.

Early population health impact studies typically modelled effects on a population cohort without forward projection of disease trends or they modelled effects on a population cohort forward in time without replacement (i.e. following the current adult population until death or end of projection). In evaluating global NCD impact of the WHO targets, Kontis et al[4] advanced this approach by modelling the population impacts between 2010 and 2025 in three five-year intervals, incorporating projections of disease trends and allowing for population growth and ageing between each modelled time interval. We have taken the modelling a step further by incorporating risk factor prevalence rates and model outputs of disease rates that are directly comparable to past trends, and integrating this with a population demographic model that stochastically forecasts trends in mortality, fertility and migration. This approach could facilitate future integration with other models, including economic models (e.g. AgMIP models, which focus on food security under climate change[1]) allowing health outcomes to be included in broader systems modelling studies. In addition, while focused on a select range of WHO risk factor targets and NCD outcomes for these analyses, the model could potentially be adapted to address a more diverse range of risks factors and disease outcomes in the future.

This modelling study illustrates the large health gains that could be achieved by addressing unhealthy risk factors for disease. For countries such as the UK that can capitalise on many decades of effort in prevention and treatment, the WHO premature mortality target is an achievable goal. But with a further two-thirds of the NCD burden still potentially preventable, it is imperative that the UK capitalises on the momentum of past decades with further effort in prevention. For low- and middle-income countries the potential benefits are likely to be even greater[4], as is the need for evidence to develop cost-effective policies for prevention in these countries. Given the growing global burden of diseases such as diabetes, depression and dementia, the WHO should consider future global targets that provide incentives for addressing these diseases, which carry a high health burden for the individual and place a substantial burden on health and social care systems in society.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

ACKNOWLEDGMENTS

We thank Jamie Sims and Jaithri Ananthapavan for assistance with coding physical activity MET
values in the Health Survey for England.

COMPETING INTERESTS

All Unified authors have completed the Competing Interest form at www.icmje.org/coi disclosure.pdf (available on request from the corresponding author) and declare (1) LC and PS have support from the Richmond Group of Charities that (www.richmondgroupofcharities.org.uk) for the submitted work; (2) LC and PS have no relationships with any companies that might have an interest in the submitted work in the previous 3 years; (3) their spouses, partners, or children have no financial relationships that may be relevant to the submitted work; and (4) LC and PS have no non-financial interests that may be relevant to the submitted work."

13 AUTHOR CONTRIBUTIONS

14 LC and PS conceived of the study, collected and analysed the data, interpreted the results and 15 contributed to writing and editing the manuscript.

16 ETHICS APPROVAL

17 Not required

18 FUNDING

19 The study was funded by a competitive grant from the Richmond Group of Charities 20 (www.richmondgroupofcharities.org.uk). The funders played no role in the study design; in the 21 collection, analysis, and interpretation of data; in the writing of the report; and in the decision to 22 submit the article for publication. The researchers were independent of the funder. All authors had

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright

full access to all of the data (including statistical reports and tables) in the study and take

responsibility for the integrity of the data and the accuracy of the data analysis.

Transparency declaration: The lead author (the manuscript's guarantor) affirms that the manuscript

- is an honest, accurate, and transparent account of the study being reported; that no important
- aspects of the study have been omitted; and that any discrepancies from the study as planned (and,
- if relevant, registered) have been explained.

DATA SHARING

- ble. No additional data available.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2

1.

REFERENCES

1

BMJ Open

Rosenzweig C, Jones J, Hatfield J, et al. The agricultural model intercomparison and

2	
2 3	
ں ۸	
4	
5	
6 7	
7	
8	
0	
9	
1	0 1
1	1
1	2
	3
	4
1	5
	6
1	7
1	7
1	8
1	9
2	0
$\overline{2}$	1
2	8901234567890123456789
2	2
2	3
2	4
2	5
<u>~</u>	6
2	0
2	7
2	8
2	9
2	0
С С	0
3	1
3	2
3	3
ັ	1
2	-
3	5
3	6
3	7
Q	8
2	0
3 ∕	9
4	0
4	1
	2
	3
	4
4	4
	5
4	6
4	7
	8
4	9
5	0
5	1
5	2
5	3
0 7	ں ۱
C	4
5	5
5	6
5	7
0 F	0
5	8
5	9
c	Λ

3 improvement project (AgMIP): protocols and pilot studies. Agricultural and Forest Meteorology. 4 2013;170:166-82. 5 2. United Nations. Political declaration of the High-level Meeting of the General Assembly on 6 the Prevention and Control of Non-communicable Diseases. United Nations General Assembly, Sixty-7 sixth session, Agenda item 117, 2011. 8 3. WHO. Global action plan for the prevention and control of noncommunicable diseases 9 2013–2020. Geneva: World Health Organization, 2013. 10 4. Kontis V, Mathers CD, Rehm J, et al. Contribution of six risk factors to achieving the 25×25 11 non-communicable disease mortality reduction target: a modelling study. The Lancet. 12 2014;384(9941):427-37. 13 Beaglehole R, Bonita R, Ezzati M, et al. NCD Countdown 2025: accountability for the 25× 25 5. 14 NCD mortality reduction target. The Lancet. 2014;384(9938):105-7. 15 6. Pearce N, Ebrahim S, McKee M, et al. The road to 25× 25: how can the five-target strategy 16 reach its goal? The lancet global health. 2014;2(3):e126-e8. 17 7. WHO. Health in 2015: from MDGs, Millennium Development Goals to SDGs, Sustainable 18 Development Goals. Geneva: World Health Organization, 2015. 19 [15 December 2015]. Available from: 8. The Richmond Group of Charities. 20 http://www.richmondgroupofcharities.org.uk/. 21 9. Joint Health Surveys Unit. Health Survey for England 2013 (and previous editions). Leeds: 22 Health and Social Care Information Centre, 2014. 23 10. McPherson K, Marsh T, Brown M. Foresight. Tackling obesities - modelling future trends in 24 obesity and the impact on health. London: Government Office for Science, 2007. 25 11. WHO. Noncommunicable diseases global monitoring framework: indicator definitions and 26 specifications. Geneva: World Health Organization, 2014. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright

BMJ Open 12. He FJ, Li J, MacGregor GA. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. BMJ. 2013;346. 13. Baumgart M, Snyder HM, Carrillo MC, et al. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. Alzheimer's & Dementia. 2015;11(6):718-26. 14. Valkanova V, Ebmeier KP. Vascular risk factors and depression in later life: a systematic review and meta-analysis. *Biol Psychiatry*. 2013;73(5):406-13. 15. Cheng G, Huang C, Deng H, et al. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J. 2012;42(5):484-91. 16. Lim S, Vos T, Flaxman A, et al. The burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions 1990-2010: a systematic analysis. The Lancet. 2013;380(9859):2224-60. 17. Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. The Lancet. 2009;373(9669):1083-96. 18. Norat T, Aune D, Vieira R, et al. The Associations between Food, Nutrition and Physical

Activity and the Risk of Pancreatic Cancer. WCRF/AICR Systematic Literature Review Continuous Update Project Report, 2011.

19. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220-9.

20. Beydoun M, Beydoun H, Wang Y. Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis. Obes Rev. 2008;9(3):204-18.

21. Thun MJ, Apicella LF, Henley SJ. Smoking vs other risk factors as the cause of smoking-attributable deaths. Confounding in the courtroom. JAMA. 2000;284(6):706-12.

22. Willi C, Bodenmann P, Ghali WA, et al. Active smoking and the risk of type 2 diabetes: A systematic review and meta-analysis. JAMA. 2007;298(22):2654-64.

23. Gandini S, Botteri E, Iodice S, et al. Tobacco smoking and cancer: A meta-analysis. Int J

Cancer. 2008;122(1):155-64.

BMJ Open

2	1	24.	Lee Y-CA, Cohet C, Yang Y-C, et al. Meta-analysis of epidemiologic studies on cigarette
3 4	2	smoking	g and liver cancer. <i>Int J Epidemiol</i> . 2009:dyp280.
5		_	
6 7	3	25.	Luger TM, Suls J, Vander Weg MW. How robust is the association between smoking and
8 9	4	depress	ion in adults? A meta-analysis using linear mixed-effects models. Addict Behav.
10 11	5	2014;39	0(10):1418-29.
12 13	6	26.	Zhong G, Wang Y, Zhang Y, et al. Smoking Is Associated with an Increased Risk of Dementia: A
14 15 16	7	Meta-A	nalysis of Prospective Cohort Studies with Investigation of Potential Effect Modifiers. PLoS
17 18	8	<i>ONE</i> . 20	15;10(3):e0118333.
19 20	9	27.	Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart
21 22	10	disease	in women compared with men: a systematic review and meta-analysis of 64 cohorts
23 24	11	includin	g 858,507 individuals and 28,203 coronary events. Diabetologia. 2014;57(8):1542-51.
25 26	12	28.	Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared
27 28 29	13	with me	en: a systematic review and meta-analysis of 64 cohorts, including 775 385 individuals and 12
30 31	14	539 stro	kes. <i>The Lancet</i> . 2014;383(9933):1973-80.
32 33	15	29.	Rotella F, Mannucci E. Diabetes mellitus as a risk factor for depression. A meta-analysis of
34 35	16	longitud	linal studies. Diabetes Res Clin Pract. 2013;99(2):98-104.
36 37	17	30.	Gudala K, Bansal D, Schifano F, et al. Diabetes mellitus and risk of dementia: a meta-analysis
38 39	18	of prosp	pective observational studies. Journal of diabetes investigation. 2013;4(6):640-50.
40 41 42	19	31.	Lewington S. Prospective studies collaboration. Age-specific relevance of usual blood
43 44	20	pressure	e to vascular mortality: a meta-analysis of individual data for one million adults in 61
45 46	21	prospec	tive studies (vol 360, pg 1903, 2002). <i>Lancet</i> . 2003;361(9362):1060
47 48	22	32.	Shield KD, Parry C, Rehm J. Chronic diseases and conditions related to alcohol use. Alcohol
49 50	23	research	h: current reviews. 2014;35(2):155.
51 52	24	33.	Patra J, Taylor B, Irving H, et al. Alcohol consumption and the risk of morbidity and mortality
53 54 55	25	for diffe	rent stroke types - a systematic review and meta-analysis. BMC Public Health. 2010;10.
55 56 57	26	34.	Baliunas DM, Taylor BM, Irving HM, et al. Alcohol as a risk factor for type 2 diabetes: a
58 59 60	27	systema	atic review and meta-analysis. <i>Diabetes Care</i> . 2009;32(11):2123.


BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright.

BMJ Open

1	35. Rehm J, Taylor B, Mohapatra S, et al. Alcohol as a risk factor for liver cirrhosis: A systematic
2	review and meta-analysis. Drug Alcohol Rev. 2010;29(4):437-45.
3	36. Corrao G, Bagnardi V, Zambon A, et al. A meta-analysis of alcohol consumption and the risk
4	of 15 diseases. Prev Med. 2004;38(5):613-9.
5	37. Forouzanfar MH, Alexander L, Anderson HR, et al. Global, regional, and national comparative
6	risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of
7	risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013.
8	The Lancet. 2015;386:2287-323.
9	38. Physical Activity Guidelines Advisory Committee. Physical Activity Guidelines Advisory
10	Committee Report. Washington, DC: U.S. Department of Health and Human Services, 2008.
11	39. Blondell SJ, Hammersley-Mather R, Veerman JL. Does physical activity prevent cognitive
12	decline and dementia?: A systematic review and meta-analysis of longitudinal studies. BMC Public
13	Health. 2014;14(1):510.
14	40. Fishman G. Monte Carlo: concepts, algorithms, and applications. New York: Springer-Verlag
15	1995.
16	41. University of California Berkeley (USA), Max Planck Institute for Demographic Research
17	(Germany). Human Mortality Database [2 April 2015]. Available from: www.mortality.org.
18	42. Max Planck Institute for Demographic Research (Germany), Vienna Institute of Demography
19	(Austria). Human Fertility Database [29 April 2015]. Available from: www.humanfertility.org.
20	43. Hyndman RJ, Booth H, Yasmeen F. Coherent mortality forecasting: the product-ratio method
21	with functional time series models. <i>Demography</i> . 2013;50(1):261-83.
22	44. Salomon JA, Murray CJ. The epidemiologic transition revisited: compositional models for
23	causes of death by age and sex. Population and Development Review. 2002;28(2):205-28.
24	45. World Health Organization. WHO Mortality Database [4 November 2014]. Available from:
25	http://www.who.int/healthinfo/statistics/mortality_rawdata/en/.
26	46. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to
27	2030. PLoS Med. 2006;3(11):e442.

BMJ Open

	1	47. Naghavi M, Makela S, Foreman K, et al. Research Algorithms for enhancing public health
	2	utility of national causes-of-death data. Popul Health Metr. 2010;8:9.
	3	48. The World Bank. World Development Indicators [1 May 2015]. Available from:
	4	http://data.worldbank.org/data-catalog/world-development-indicators.
	5	49. Greene WH. Econometric analysis. 5th ed. Upper Saddle River, New Jersey: Prentice Hall;
	6	2003.
	7	50. WHO. National health accounts: country health information Geneva: World Health
	8	Organization; 2015 [15 December 2015]. Available from:
	9	http://apps.who.int/nha/database/Country_Profile/Index/en.
2	10	51. Donohue JM, Pincus HA. Reducing the societal burden of depression. <i>Pharmacoeconomics</i> .
2	11	2007;25(1):7-24.
2	12	52. Luengo-Fernandez R, Leal J, Gray A. UK research spend in 2008 and 2012: comparing stroke,
2	13	cancer, coronary heart disease and dementia. BMJ open. 2015;5(4):e006648.
2	14	53. Kingdon D. Health research funding: Mental health research continues to be underfunded.
-	15	<i>BMJ</i> . 2006;332(7556):1510.
2	16	54. Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe 2010. <i>Eur</i>
2	17	Neuropsychopharmacol. 2011;21(10):718-79.
2	18	55. Cecchini M, Sassi F, Lauer JA, et al. Tackling of unhealthy diets, physical inactivity, and
2	19	obesity: health effects and cost-effectiveness. The Lancet. 2010;376(9754):1775-84.
2	20	56. Cobiac LJ, Vos T, Doran C, et al. Cost-effectiveness of interventions to prevent alcohol-related
2	21	disease and injury in Australia. Addiction. 2009;104(10):1646-55.
2	22	57. Cobiac LJ, Vos T, Veerman JL. Cost-effectiveness of interventions to reduce dietary salt
2	23	intake. <i>Heart</i> . 2010;96(23):1920-5.
2	24	58. Nghiem N, Blakely T, Cobiac LJ, et al. Health and economic impacts of eight different dietary
2	25	salt reduction interventions. PLoS ONE. 2015;10(4).
2	26	59. Hall KD, Sacks G, Chandramohan D, et al. Quantification of the effect of energy imbalance on
2	27	bodyweight. <i>The Lancet</i> . 2011;378(9793):826-37.



⊿0

FIGURES

Figure 1 The modelled relationships between the WHO risk factor targets and CHD or stroke (Note: PA – physical activity; BMI – body mass index; BP – blood pressure; CHD – coronary heart disease).

Figure 2 Projected trends in the probability of dying prematurely from non-communicable disease for the WHO risk factor target scenarios.

Figure 3 Non-communicable disease deaths and YLDs that are averted or delayed between 2010 and 2025, for the combined risk factor target scenario.

(Note: the small increase in COPD YLDs is due to a shift in the age distribution of the population, primarily as a result of reductions in CHD and stroke

mortality, and does not reflect an increase in COPD rates).

Figure 4 DALYs averted for the WHO risk factor target scenarios.

Figure 5 DALYs averted for the combined WHO risk factor target scenario and the ideal risk reduction scenario.

SUPPORTING DOCUMENTS

Appendix 1: Calculating the combined effect of meeting all risk factor targets

Appendix 2: Ideal risk scenario results

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright.

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright.




Figure 1 The modelled relationships between the WHO risk factor targets and CHD or stroke (Note: PA – physical activity; BMI – body mass index; BP – blood pressure; CHD – coronary heart disease).

209x297mm (300 x 300 DPI)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml




Figure 2 Projected trends in the probability of dying prematurely from non-communicable disease for the WHO risk factor target scenarios.

297x420mm (300 x 300 DPI)

Page 32 of 42

BMJ Open




Figure 3 Non-communicable disease deaths and YLDs that are averted or delayed between 2010 and 2025, for the combined risk factor target scenario. (Note: the small increase in COPD YLDs is due to a shift in the age distribution of the population, primarily as a result of reductions in CHD and stroke mortality, and does not reflect an increase in COPD rates).

297x420mm (300 x 300 DPI)

BMJ Open

Men averted (per 100,000 population) DALYS Yea Womer lation averted (per 100,000 pop DALYS Yea Raised blood pressure --- Obesity + Tobacco use ---- Diabetes

----- Physical inactivity

Combined scenario

Figure 4 DALYs averted for the WHO risk factor target scenarios.

209x297mm (300 x 300 DPI)

BMJ Open: first published as 10.1136/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright.




Figure 5 DALYs averted for the combined WHO risk factor target scenario and the ideal risk reduction scenario.

209x297mm (300 x 300 DPI)

the ideal risk reduction

.ng the com.

For the combined risk factor target scenario the population impact fractions (PIFs) for coronary heart disease (CHD) and stroke were calculated multiplicatively from the individual PIFs for physical activity (PA), body mass index (BMI), blood pressure (BP), diabetes, alcohol and tobacco.

$$PIF_{Combined} = 1 - (1 - PIF_{BP}) \times (1 - PIF_{Diab}) \times (1 - PIF_{PA}) \times (1 - PIF_{BMI}) \times (1 - PIF_{Alc}) \times (1 - PIF_{Tob})$$

Figure 1 shows our conceptual model of the relationships between the risk factor targets and CHD, and Table 1 summarises the methods for calculation of the individual PIFs via the different pathways shown in Table 1. Notes below the table provide further detail on methods used to prevent double-counting of effects.

Figure 1 The modelled relationships between the WHO risk factor targets and CHD (NB. an identical process was used to estimate the combined risk factor effect on stroke.)




Table 1 Methods for the calculation of population impact fractions (PIFs) for the combined risk factor scenario

PIF	Ca	Iculations	Sources	
PIF _{BP}	1. 2. 3. 4.	Calculate the full PA target effect on BP (i.e. directly and via BMI) Calculate the remaining BMI target effect on BP (i.e. the BMI effect excluding PA – see Note 1 below) Calculate the Salt target effect on BP Sum the effects on BP from steps 1 to 3, and calculate the CHD/Stroke	Cornelissen et al[Neter et al[2] He et al[3] Prospective Collaboration[4]	1] Studies
	5. <i>PII</i>	PIF Calculate the CHD/Stroke PIF for the Hypertension target effect F _{BP} = the biggest of the PIFs calculated in steps 4 and 5		
PIF_{Diab}	1.	Calculate the full PA target effect on Diabetes (i.e. directly and via BMI), using RR adjusted for BMI	Wahid et al Unde Prospective Collaboration[5]	r review Studies

	 Calculate the remaining BMI target effect on Diabetes (i.e. the BMI effect excluding PA – see Note 1 below), using RR adjusted for PA (using adjustment estimate) 	usted for PA (using (adjustment estimate) Peters et al[7,8]	
	 Sum the effects on Diabetes from steps 1 and 2, and calculate the CHD/Stroke PIF 		
	4. Calculate the CHD/Stroke PIF for the Diabetes target effect <i>PIF_{Diab}</i> = the biggest of the PIFs calculated in steps 4 and 5		
PIF _{PA} (excluding effects via BP and Diabetes)	PIF_{PA} = PIF calculated for the direct PA using RR CHD/Stroke estimates (see Note 2 below)	Wahid et al Under review Health Survey for England 2012[9] Global Burden of Disease[10]	
PIF _{BMI} (excluding effects via BP and Diabetes)	<i>PIF_{BMI}</i> = PIF calculated for the direct BMI using RR CHD/Stroke estimates (see Note 2 below)	Prospective Studies Collaboration[5] Cobiac et al[6] (adjustment estimate) Health Survey for England (HSE) 2012[9] Global Burden of Disease (GBD)[10]	
PIF _{Alc}	PIF_{Alc} = PIF calculated using RR CHD/Stroke estimates from meta-analyses	Shield et al[11] Patra et al[12]	
PIF _{Tob}	PIF_{Tob} = PIF calculated using RR CHD/Stroke estimates from meta-analyses	Cancer Prevention Study II[13]	

Note 1 – calculating the PA target effect on BMI

To prevent double-counting of effects of changes in physical activity and BMI in the combined scenario, we estimated the change in BMI that could be attributed to the physical activity changes. Change in body weight was estimated using energy balance equations described by Hall et al[14], assuming change in fat free mass remains constant as a proportion of change in body weight[15].

Resting energy expenditure, a component of the energy balance calculations, was estimated from regression models derived by Mifflin et al[16] from a subset of healthy subjects enrolled in a diet and heart disease study. Physical activity levels, also a component of the energy balance calculations, were estimated from the total MET hours spent in all activities over the day. We used FAO[17] estimates of energy costs for sleeping, personal care (dressing, showering), eating, cooking and sitting/sedentary activities (e.g. office work, selling produce, tending shop). Energy costs of time spent in all other activities, such as sports and fitness activities, occupational lifting, active travel and home activities (e.g. housework) were determined from responses to physical activity survey questions in the Health Survey for England[9] and the Physical Activity Compendium[18]. We assumed that the increase in physical activity from reaching the WHO target, if it was to be sustained in the population, would need to result from a reduction in time spent sitting/sedentary rather than in time spent on sleeping, personal care, eating or cooking.

We calculated change in body weight from meeting the physical activity target by solving the energy balance equations using least squares and the generalised reduced gradient nonlinear method of optimisation in Excel. We then calculated change in BMI using height data from the Health Survey for England. From this we could distinguish the *remaining* BMI effect (i.e. the proportion of the BMI target effect that is not attributable to achieving the PA target).

Note 2 – calculating RRs for pathways not mediated by BP or Diabetes

To calculate the PIF_{PA} and PIF_{BMI} components of the combined PIF equation, we needed to know relative risks of CHD and Stroke associated with changes in PA and BMI that would *not* be mediated by either diabetes or BP (since the mediated contributions would already be counted in the PIF_{Diab} and PIF_{BP} calculations). Since we did not have published estimates of these RRs, we derived them using an optimisation process in Excel, assuming that the fractions of the disease attributable to the risk factor via the direct and indirect pathways would have to sum to the total attributable fraction.

This process is illustrated in Figure 2, with physical activity as the risk factor, diabetes as the intermediate variable and CHD as the disease (pathway A is the unknown). Using optimisation, we determined what the relative risks for CHD (pathway A) would need to be so that the total fraction of CHD attributable to PA (pathway C) would be equal to the sum of the contributions from PA directly (pathway A) and from PA via diabetes (pathway B).

The optimisation was performed twice. First we used the PA-CHD RR (Wahid et al meta-analysis, adjusted for BMI), the diabetes prevalence (HSE) and CHD mortality (GBD 2010) to derive a PA-CHD RR that is not mediated by diabetes (but may be mediated by BP). Second, we used the 'partly-mediated' RR output from the first step, along with the BP distribution (HSE) and CHD mortality (GBD 2010) to derive a PA-CHD RR that is not mediated by either diabetes or BP. This was the RR used in the calculation of the *PIF*_{PA} for the combined analyses.

The same methods were used to solve for the relative risks of stroke; and the whole process was repeated with BMI as the risk factor, using BMI RR estimates of CHD and stroke (for pathway C) from the Prospective Studies Collaboration[5].




Figure 2 Conceptual diagram of the pathways between risk factor (physical activity), intermediate variable (diabetes) and disease (CHD) in the optimisation process.

References

- 1. Cornelissen VA, Fagard RH (2005) Effects of endurance training on blood pressure, blood pressure– regulating mechanisms, and cardiovascular risk factors. Hypertension 46: 667-675.
- 2. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM (2003) Influence of weight reduction on blood pressure a meta-analysis of randomized controlled trials. Hypertension 42: 878-884.
- 3. He FJ, Li J, MacGregor GA (2013) Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. BMJ: British Medical Journal 346.
- 4. Prospective Studies Collaboration (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. The Lancet 360: 1903-1913.
- 5. Prospective Studies Collaboration (2009) Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. The Lancet 373: 1083-1096.
- 6. Cobiac LJ, Vos T, Veerman JL (2010) Cost-effectiveness of Weight Watchers and the Lighten Up to a Healthy Lifestyle program. Australian and New Zealand Journal of Public Health 34: 240-247.
- 7. Peters SA, Huxley RR, Woodward M (2014) Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia 57: 1542-1551.
- Peters SA, Huxley RR, Woodward M (2014) Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775 385 individuals and 12 539 strokes. The Lancet 383: 1973-1980.
- 9. Joint Health Surveys Unit (2014) Health Survey for England 2013 (and previous editions). Leeds: Health and Social Care Information Centre.
- Wang H, Dwyer-Lindgren L, Lofgren KT, Rajaratnam JK, Marcus JR, et al. (2013) Age-specific and sex-specific mortality in 187 countries, 1970–2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet 380: 2071-2094.
- 11. Shield KD, Parry C, Rehm J (2014) Chronic diseases and conditions related to alcohol use. Alcohol research: current reviews 35: 155.
- 12. Patra J, Taylor B, Irving H, Roerecke M, Baliunas D, et al. (2010) Alcohol consumption and the risk of morbidity and mortality for different stroke types a systematic review and meta-analysis. BMC Public Health 10.
- 13. Thun MJ, Apicella LF, Henley SJ (2000) Smoking vs other risk factors as the cause of smokingattributable deaths: confounding in the courtroom. Jama 284: 706-712.
- 14. Hall KD, Sacks G, Chandramohan D, Chow CC, Wang YC, et al. (2011) Quantification of the effect of energy imbalance on bodyweight. The Lancet 378: 826-837.
- 15. Heitmann BL, Garby L (2002) Composition (lean and fat tissue) of weight changes in adult Danes. The American journal of clinical nutrition 75: 840-847.
- Mifflin MD, St Jeor ST, Hill LA, Scott BJ, Daugherty SA, Koh Y (1990) A new predictive equation for resting energy expenditure in healthy individuals. The American journal of clinical nutrition 51: 241-247.
- 17. FAO (2001) Human Energy Requirements: Report of a Joint FAO/WHO/UNU Expert Consultation. Rome: Food and Agriculture Organization of the United Nations, World Health Organization, United Nations University.

18. Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett Jr DR, et al. (2011) 2011 Compendium J. te of t of Physical Activities: a second update of codes and MET values. Medicine and science in sports and exercise 43: 1575-1581.

36/bmjopen-2016-012805 on 4 April 2017. Downloaded from http://bmjopen.bmj.com/ on April 16, 2024 by guest. Protected by copyright





BMJ Open

36/bmjopen-2016-

	30-69 years		ි ග 0 70	$\frac{5}{2}$ 70+ years	
	Men	Women	Men $\stackrel{+}{\underline{}}$	Women	
Deaths			Men <u>Ap</u> ril 11 20		
Obesity	63,000 (46,000 to 80,000)	26,000 (13,000 to 39,000)	230,000 (170,000 to 280,000) .7	170,000 (120,000 to 230,000)	
Tobacco use	88,000 (72,000 to 100,000)	61,000 (51,000 to 70,000)	360,000 (290,000 to 430,000) 🛛	290,000 (230,000 to 340,000)	
Diabetes	19,000 (16,000 to 23,000)	7,800 (6,300 to 9,200)	98,000 (80,000 to 120,000)	96,000 (78,000 to 110,000)	
Raised blood pressure	24,000 (23,000 to 25,000)	9,300 (8,600 to 10,000)	ົ້ລ 110,000 (100,000 to 110,000) <u>ອ</u>	98,000 (92,000 to 100,000)	
Salt intake	24,000 (23,000 to 25,000)	6,200 (5,900 to 6,500)	95,000 (91,000 to 99,000) from	62,000 (59,000 to 64,000)	
Harmful alcohol use	6,800 (-31,000 to 45,000)	20,000 (-2,300 to 43,000)	-8,400 (-120,000 to 100,000)	72,000 (-170,000 to 320,000)	
Physical inactivity	10,000 (7,200 to 13,000)	3,700 (2,700 to 4,700)	48,000 (34,000 to 62,000)	42,000 (31,000 to 54,000)	
Combined scenario	190,000 (150,000 to 230,000)	94,000 (69,000 to 120,000)	800,000 (660,000 to 940,000) g	640,000 (460,000 to 810,000)	
YLDs (Thousands)			n.br		
Obesity	390,000 (320,000 to 470,000)	320,000 (250,000 to 390,000)	720,000 (570,000 to 860,000) o	640,000 (490,000 to 790,000)	
Tobacco use	770,000 (700,000 to 840,000)	860,000 (810,000 to 920,000)	1,300,000 (1,200,000 to 1,500,000)	1,500,000 (1,400,000 to 1,600,000	
Diabetes	620,000 (610,000 to 630,000)	510,000 (510,000 to 520,000)	1,100,000 (1,000,000 to 1,100,000)	990,000 (970,000 to 1,000,000)	
Raised blood pressure	75,000 (71,000 to 79,000)	51,000 (46,000 to 55,000)	170,000 (160,000 to 180,000) $\frac{\Xi}{2}$	130,000 (120,000 to 140,000)	
Salt intake	76,000 (72,000 to 79,000)	36,000 (34,000 to 37,000)	رو (150,000 (150,000 to 160,000) کې	83,000 (80,000 to 87,000)	
Harmful alcohol use	-82,000 (-260,000 to 100,000)	-120,000 (-260,000 to 23,000)	-120,000 (-410,000 to 170,000	-180,000 (-450,000 to 80,000)	
Physical inactivity	69,000 (58,000 to 80,000)	60,000 (51,000 to 70,000)	140,000 (120,000 to 170,000) පු	130,000 (110,000 to 160,000)	
Combined scenario	1,600,000 (1,500,000 to 1,700,000)	1,500,000 (1,400,000 to 1,600,000)	2,900,000 (2,700,000 to 3,100,000)	2,800,000 (2,500,000 to 3,000,000	
NB. Values are mean and	95% uncertainty intervals.		rotected by copyright.		

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml